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Hydrogen peroxide inducible clone-5/Androgen Receptor Activator 55 (Hic-5/ARA55) is a 
group III LIM domain protein that functions at focal adhesion complexes as well as in the 
nucleus as a nuclear receptor coactivator.  Because the interaction of the androgen receptor (AR) 
with Hic-5/ARA55 results in enhanced androgen-induced transcription, we analyzed Hic-
5/ARA55 expression in prostate tissue sections from normal human donors and prostate cancer 
patients.  In each sample, Hic-5/ARA55 expression was confined to the stromal compartment of 
the prostate.  Furthermore, in a human prostate stromal cell line (i.e. WPMY-1 cells) Hic-
5/ARA55 was localized both at focal adhesion complexes and within the soluble cytoplasmic 
compartment.  The ability of Hic-5/ARA55 to shuttle between the nuclear and cytoplasmic 
compartments within WPMY-1 cells was revealed upon inhibition of nuclear export with 
leptomycin B (LMB).  siRNA ablation experiments established endogenous Hic-5/ARA55 as a 
coactivator for both viral and endogenous cellular AR-regulated genes.  Furthermore, chromatin 
immunoprecipitation (ChIP) analysis showed androgen-dependent recruitment of Hic-/ARA55 to 
the promoter of the stromal androgen-responsive KGF gene.  Using the A1-2 derivative of T47D 
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breast cancer cells, we examined the mechanism by which Hic-5/ARA55 potentiates nuclear 
receptor transactivation.  Hic-5/ARA55 was found to be an important component of 
glucocorticoid receptor (GR)-coactivator complexes in A1-2 cells since ablation of Hic-
5/ARA55 expression by RNA interference-mediated silencing reduced GR transactivation.  As 
shown by ChIP assays, Hic-5/ARA55 is recruited to glucocorticoid-responsive promoters of the 
MMTV, c-fos, and p21 genes in response to glucocorticoid treatment.  Results from sequential 
ChIP assays established that Hic-5/ARA55 associates with the corepressor, NCoR, in the 
absence of glucocorticoids.  However, upon glucocorticoid stimulation, Hic-5/ARA55 interacts 
with GR-coactivator containing complexes at these promoters.  Ablation of Hic-5/ARA55 
expression resulted in reduction of both TIF-2 and p300 recruitment to glucocorticoid-responsive 
promoters.  These data provide the first demonstration of a stromal-specific AR coactivator that 
has an impact on an androgen regulated growth factor that is essential for stromal/epithelial cell 
communication in the prostate.  Furthermore, these results suggest that Hic-5/ARA55 is required 
for optimal GR-mediated gene expression possibly by providing a scaffold that organizes or 
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The prostate gland secretes the main protein components found in seminal fluid.  
Structurally, the prostate is composed of both a glandular epithelium and a fibromuscular 
stroma, which are separated by a basement membrane.  The epithelial compartment is 
composed of two types of epithelium, basal and secretory.  Basal epithelial cells secrete 
proteins found in the basement membrane, and some may constitute secretory epithelial 
stem cells (4, 5).   The secretory epithelial compartment is responsible for production and 
secretion of enzymes, such as human prostate acid phosphatase (hPAP) and prostate 
specific antigen (PSA), which are found in seminal fluid.  The stromal compartment is 
composed of smooth muscle cells, fibroblasts, endothelial cells, nerve cells, and 
lymphocytes.  The stroma secretes growth factors and cytokines responsible for normal 
growth and development of the epithelial compartment (6). 
 
Epithelial-Stromal Interactions in the Prostate 
 
Communication between the epithelial and stromal compartments of the prostate, 
mediated by growth factors and cytokines, is crucial for the maintenance of prostate 
growth and function (Figure 1, 7, 8).  Examples of such growth factors in the prostate 
include transforming growth factor beta (TGF-β), transforming growth factor alpha 
(TGF-α), epidermal growth factor (EGF), keratinocyte growth factor (KGF), fibroblast 
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growth factor-2 (FGF-2), and insulin-like growth factor (IGF) (9, 10).  Most of these 
growth factors enhance both growth and development of the prostate, although TGF-β 
may negatively affect prostate growth (2). 
 
During prostate development, the urogenital sinus mesenchyme (UGM) stimulates 
epithelial differentiation, ductal branching, and proliferation (11).  Conversely, signals 
derived from the urogenital epithelium (UGE) promote mesenchymal differentiation (12).  
Along with epithelial-stromal communication, androgen signaling through AR is crucial 
for prostate development (13).  Reconstitution experiments with isolated stromal and 
epithelial cells performed by Cunha and Lang illustrated the necessity for functional AR 
in the UGM for the development of a functional prostate (14).  In these studies, prostate 
tissue was derived from either normal or testicular feminized (TFM) mice that have a 
loss-of-function mutation in the AR gene. Whereas combining TFM UGE and normal 
UGM produced normal prostate organ formation in the presence of androgen, analogous 
tissue reconstitutions with normal UGE and TFM UGM did not support prostate 
organogenesis.  This correlates with AR expression patterning seen in the developing 
prostate.  Specifically, before and during prostatic bud formation, AR expression is 
restricted to the UGM (13).  These data suggest that AR controls the expression of a 
soluble factor in the UGM that is necessary for proper epithelial differentiation and thus 





































Figure 1. Stromal-epithelial interactions in the prostate.  Communication between the 
stromal and epithelial compartments of the prostate via growth factor and cytokines can 
either induce or repress cell growth.  KGF, a paracrine mediator of epithelial-stromal 
interactions, is produced in the stromal compartment while its receptor is expressed solely 
in the epithelial compartment, resulting in epithelial proliferation (1).  Alternatively, TGF-
β is produced by both the epithelial and stromal compartment and functions to negatively 
influence epithelial cell growth by inhibiting cell division as well as inducing apoptosis 
(2).  Finally, FGF2 is produced by the both the epithelial and stromal compartment, acting 




Androgens and Prostate Function 
 
Circulating androgens derived primarily from the testes also contribute to normal growth 
and development of the prostate gland (15). Testicular Leydig cells secrete testosterone 
(T) that is converted in the prostate to dihydrotestosterone (DHT) by 5α-reductase (16).  
Androgen action in both stromal and epithelial compartments of the prostate is mediated 
through AR (5).  In the epithelial compartment, androgens are required for both 
proliferative and secretory functions of the prostate (12).  For example, androgens induce 
the expression of prostate-specific secretory proteins, including human prostate acid 
phosphatase (hPAP), prostate specific antigen (PSA), and prostate-specific kallikrein 
(hK2) (17, 18).  In the stromal compartment, AR regulates the expression of various 
growth factors such as KGF (FGF-7), a member of the fibroblast growth factor family 
(14, 19-21).  KGF is exclusively expressed in the stromal compartment of the prostate 
while its receptor, a spliced variant of the FGF type 2 receptor (FGFR2IIIb), is expressed 
solely in the epithelial compartment (3).  These characteristics suggest that KGF is a 
paracrine mediator of signaling from the stroma to the epithelial compartment that can 




The nuclear receptors comprise a large family of ligand-dependent transcription factors 
that regulate target gene expression through a variety of mechanisms.  Receptors for 
steroid hormones include estrogen receptor (ER), androgen receptor (AR), progesterone 
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receptor (PR), and glucocorticoid receptor (GR).  In the absence of hormone, steroid 
receptors are associated with heat shock proteins and immunophilins (23).  Once bound 
by ligand, steroid receptors undergo a conformational change, permitting homo-
dimerization and translocation into the nucleus.  Upon entering the nucleus, steroid 
receptors induce gene expression by binding hormone response elements (HREs) located 
in the promoter regions of target genes.  Alternatively, nonsteroidal nuclear receptors 
including thyroid hormone receptor (TR), vitamin D receptor (VDR), retinoic acid 
receptor (RAR), and peroxisome proliferators activated receptor (PPAR) are nuclear 
proteins regardless of the presence or absence of ligand.  In the absence of ligand, these 
receptors form heterodimers with retinoid X receptor (RXR), binding HREs in 
association with a repressor complex and preventing target gene expression.  Upon ligand 
binding, the repressor complex disassociates and gene expression ensues (24).  Along 
with steroid and nonsteroidal nuclear receptors, orphan receptors such as constitutive 
androstane receptor (CAR), liver X receptor (LXR), pregnane X receptor (PXR), 
farnesoid X receptor (FXR) and hepatocyte nuclear factor (HNF) are also part of the 
nuclear receptor family of transcription factors.  Orphan receptors were first grouped 
together as proteins that resemble nuclear receptors and most of their physiological 
ligands were not known.  However, in recent years, a diverse range of endogenous and 
xenobiotic lipophilic compounds have been identified as ligands for some of the orphan 
receptors.  For example, bile acids activate FXR-mediated gene expression while LXR is 
activated by cholesterol (reviewed (25). 
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Structurally, nuclear receptors are modular proteins composed of an amino terminal 
domain (NTD), a central DNA binding domain (DBD), and a carboxyl terminal ligand 
binding domain (LBD) (Figure 2).  Both the DBD and LBD are highly conserved while 
the NTD is more variable.  Both the NTD and LDB contain activation function domains, 
AF-1 and AF-2 respectively, which potently activate transcription of nuclear receptor 
target genes when expressed.  However, AF-1 activates nuclear receptor-mediated gene 
expression independent of ligand whereas AF-2 activation requires ligand (26).   
 
Once in the nucleus, ligand-bound nuclear receptors are recruited to target gene 
promoters either through direct binding to HREs or association with other promoter-
bound transcription factors to positively or negatively affect gene expression (27).  For 
example, prostate specific antigen (PSA) and phosphoenolpyruvate carboxykinase 
(PEPCK) are both positively regulated by AR and GR, respectively (28, 29).  
Alternatively, GR interacts with chromatin-associated NF-κB as well as AP-1 
transcription factors, repressing their transcriptional activity in a ligand dependent 
manner, termed transrepression.  Initially, it was hypothesized that GR binds NF-κΒ, 
occluding other protein interactions or recruiting histone deacetylase (HDAC) complexes, 
thus preventing NF-ΚB-mediated gene expression.  Additionally, in A549 cells, GR 
inhibits NF-κB-mediated gene expression by preventing phosphorylation of serine 2 of 
the C terminal domain of pol II, thereby preventing pol II-mediated transcription (30).  
Along with binding other transcription factors, ligand-bound nuclear receptors promote 
the recruitment of coactivator complexes that stimulate gene expression by remodeling  
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Figure 2.  Modular structure of the nuclear receptor family of transcription factors.  
Nuclear receptors are composed of three major domains:  the amino terminal domain 
(NTD), which contains the AF-1 transactivation domain (TAD), the DNA binding domain 
(DBD), and the ligand binding domain (LBD), which contains the AF-2 TAD as well as a 
domain required for receptor dimerization. 
chromatin or contacting the basal transcription machinery, thereby stabilizing the 
transcription initiation complex (31). 
 
Nuclear Receptor Coactivators 
 
Nuclear receptor coactivators enhance nuclear receptor-dependent gene expression 
through a variety of mechanisms (32).  Coactivator complexes are assembled onto 
receptor-bound promoters and stimulate nuclear receptor-mediated transcription either 
through direct interactions with the basal transcription machinery or by inducing local 
chromatin remodeling, including histone acetylation or methylation (31-36).  Some 
coactivators possess enzymatic activity such as histone acetyltransferase (HAT) and 
methyltransferase activities that post-translationally modify histone proteins to affect 
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chromatin structure, while others that lack such activities function to recruit chromatin 
modifying enzymes to active promoters. 
 
Once a potential coactivator has been isolated, it must fulfill three main criteria to be 
defined as a “classical” nuclear receptor coactivator.  For example, coactivators must 
enhance nuclear receptor-mediated gene expression without altering the basal expression 
of a target gene.  Furthermore, coactivators must reverse squelching effects observed by 
the addition of other, competing nuclear receptors.  Finally, coactivators must contain 
intrinsic activation domains, capable of activating target gene expression when fused to a 
DNA binding domain.  Although these criteria were originally used to differentiate 
coactivators from other nuclear receptor-interacting proteins, this definition may be too 
limiting as it ignores other potentially novel contributions of nuclear receptor interacting 
proteins to transactivation.     
 
Most coactivators interact with the ligand binding domain of a variety of nuclear 
receptors including GR and AR via nuclear receptor (NR) boxes such as LXXLL motifs 
(37, 38).  However, differences in binding affinities between nuclear receptors and their 
coactivators may play a role in determining the specificity of hormonal responses.  For 
example, AR can bind glucocorticoid receptor interacting protein (GRIP/TIF-2/SRC-2) 
with a higher affinity then steroid receptor coactivator-1 (SRC-1) (39).  Although both 
AR and GR interact with similar coactivators, it is postulated that unique coactivator 
complexes may be responsible for specific cellular and gene responses to each hormone.  
Furthermore, each nuclear receptor associates with specific coactivator complexes at the 
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same promoter (40).  For example, using ChIP analysis of the mouse mammary tumor 
virus (MMTV) promoter, which contains a common hormone response element capable 
of binding AR, GR, or the progesterone receptor (PR), Li et al. isolated a specific 
coactivator complex associated with PR that differed from the coactivator complex that 
bound to GR (14).  Specifically, SRC-1, RAC3, CBP, and p300 interacted with PR 
whereas TIF-2, RAC3, pCAF, and p300 interacted with GR.  Additionally, these 
alternative coactivator complexes resulted in alternative posttranslational modifications 
of histones.  Histone 4 is acetylated at lysine 5 after progesterone stimulation, and histone 
3 is phosphorylated at serine 10 as well as acetylated at lysine 14 upon glucocorticoid 
treatment (40).    
 
While many coactivators are likely to be redundant in their effects on nuclear receptor 
function in cultured cell lines, recent in vivo studies suggest that different physiological 
outcomes may result from variations in coactivator expression (35-37).  For example, 
TIF-2 and RAC3 null mice display reduced reproductive capability (41, 42).  TIF-2 null 
male mice have defective spermiogenesis and display testicular degeneration, whereas 
females display poor placental development, resulting in embryonic growth retardation 
(41).  RAC3 -/- mice have decreased mammary gland growth, ovulatory capacity, and 
litter size (42).  Alternatively, whereas SRC-1 null mice are fertile, they exhibit partial 
hormone resistance (43).  Specifically, SRC-1 -/- mice have decreased growth and 




Recently, many coactivators have been identified and classified into sub-families 
consisting of similar members.  For example, the p160 family of coactivators, designated 
nuclear receptor coactivators (SRCs) consists of SRC-1 (or NcoA1), SRC-2 (or TIF-2, 
GRIP1), and SRC-3 (or p/CIP, RAC3, ACTR, or AIB1) (24-30).  These coactivators 
share conserved sequence regions termed nuclear receptor interaction domains that 
permit interactions with a broad range of nuclear receptors.  Other coactivators that are 
distinct from the p160 family are components of large complexes, such as the vitamin D 
interacting proteins (DRIPs) and thyroid receptor associated proteins (TRAPs) (31, 32).  
Finally, many other proteins have been identified as androgen receptor activators (ARAs) 
that may utilize unique mechanisms to impact receptor transactivation that remain largely 
undefined (33, 34).  For example, ARA70, an AR-specific coactivator, may play a role in 
uncovering the agonist activity of certain anti-androgens to activate AR activity (44).  
Furthermore, a LIM domain containing protein that associates with focal adhesions, 
hydrogen peroxide-inducible clone-5 (Hic-5/ARA55) was identified as a nuclear receptor 
coactivator (45, 46).   
 
LIM Domain-Containing Proteins 
 
LIM domains are cysteine-rich motifs that may provide critical surfaces for protein-
protein interactions (47).  LIM domain proteins are grouped into three broad families 
based on their subcellular localization and function (48).  Group I LIM proteins such as 
LIM only 2 (LMO) are nuclear proteins that influence gene expression by interacting 
with transcription factors (49).  Group II LIM proteins are localized primarily in the 
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cytoplasm and function in the organization of the actin cytoskeleton (50).  Finally, group 
III LIM proteins were initially found to localize to the cytoplasm often associated with 
focal adhesion complexes, but recently, our lab as well as others have revealed distinct 
pools of group III LIM domain proteins including Hic-5/ARA55, paxillin, and Trip6 in 
the nucleus (51-53). 
 
A variety of LIM domain-containing proteins have been described that either positively 
or negatively influence gene expression (54).  For example, thyroid interacting protein 
partner (Trip6), a group III LIM domain protein, is able to both enhance and repress AP-1 
and NF-κΒ-regulated promoters by assembling different complexes in response to 
differential cellular signals (52).  Upon TPA or TNF-α treatment, Trip6 is recruited to the 
collagen I or interleukin-8 (ColI or IL-8) promoters, enhancing AP-1 and NF-κB-
mediated gene expression respectively.  However, upon glucocorticoid treatment, Trip6 
represses AP-1 and NF-κB action by tethering GR to specific promoters (52).  This 
indicates that specific signaling events can determine if Trip6 activates or represses 
specific gene expression.  Additionally, Four and a half LIM-only protein (FHL2) is also 
a LIM-domain containing protein that can both enhance or repress gene expression.  
FHL2 was initially identified as an AR-specific coactivator whose expression in the 
prostate overlaps that of AR and was later reported to influence β-catenin-mediated gene 
expression (55, 56).  The mechanism by which FHL2 coactivates β-catenin-mediated 
transcription is due in part to a physical interaction with CBP/p300, resulting in increased 
acetylation of β-catenin by CBP/p300 (55).  Acetylation of β-catenin may enhance its 
interaction with TCF4, thereby increasing β-catenin-mediated gene expression (57).  
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Interestingly, FHL2 represses β-catenin-mediated gene expression in muscle cells, 
resulting in myogenic differentiation (58).   
 
As mentioned previously, group III LIM domain containing proteins, including Hic-
5/ARA55, are predominantly localized at focal adhesions.  However, some group III LIM 
domain proteins such as zyxin, lipoma preferred partner (LPP), Trip6, paxillin, and Hic-
5/ARA55 can also be found in the nucleus (45, 51, 52, 59, 60).  In fact, distinct pools of 
Hic-5/ARA55 were found in the nucleus associated with the nuclear matrix (45).   
Although many LIM domain containing proteins have been detected in the cytoplasm and 
at focal adhesions and their nuclear export sequences have been identified, the precise 
signals that induce their translocation are mostly unknown (reviewed in (54).  For 
example, both LPP and Trip6 are detected in the nucleus after LMB treatment, indicating 
residual shuttling between the compartments (60, 61).  However, FHL2 translocates to 
the nucleus in response to activation of Rho, a small GTPase, while mechanical forces 
applied to vascular smooth muscle cells lead to nuclear accumulation of zyxin (62, 63).  
Furthermore, it has been reported that nuclear accumulation of Hic-5/ARA55 occurs in 
response to oxidants such as H2O2 (64).  However, in A1-2 cells, increased nuclear 
receptor-mediated gene expression in the presence of both ligand and H2O2 not only 
resulted in reduced nuclear receptor-mediated gene expression (unpublished results).  
Subsequent analysis of GR and Hic-5/ARA55 promoter recruitment to the MMTV 
promoter in the presence of dexamethasone (Dex) and H2O2 by ChIP analysis revealed 
less GR and Hic-5/ARA55 promoter localization in the presence of H2O2 (unpublished 
results). 
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 In addition to nuclear receptors, Hic-5/ARA55 functions as a coactivator for Sp1, 
enhancing p21 expression (65).  In this case, Hic-5/ARA55, forced into the nucleus with 
an added heterologous nuclear localization signal (NLS), influences p21 expression by 
interacting directly with Smad3 and indirectly with Sp1 and p300 (65).   Although a 
direct interaction between Sp1 and Hic-5/ARA55 has not been detected, Hic-5/ARA55 
has been found to associate with Smad3.  Also, a LIM 4 deletion mutant of Hic-5/ARA55 
interfered with the coactivation properties of p300, suggesting a functional interaction 
between these coactivators.   
 
Along with AR and GR, Hic-5/ARA55 serves as a coactivator for PPARγ (66).  
Specifically, Hic-5/ARA55 enhances PPARγ-mediated induction of genes such as keratin 
20, a cytokeratin that is expressed in mature intestinal epithelium as well as 
uroepithelium, L-FABP, a fatty acid binding protein found in differentiated intestinal 
epithelium, and KLF, a zinc finger transcription factor that is also expressed in intestinal 
epithelial cells (67-69).  Furthermore, siRNA ablation of Hic-5/ARA55 expression 
reduced the expression of PPARγ-regulated genes.  Finally, a role for Hic-5/ARA55 in 
epithelial differentiation induced by PPARγ was reported.  Forced expression of Hic-
5/ARA55 in preadipocytes not only inhibited adipocyte differentiation but also induced 
epithelial gene expression in these mesenchymal cells (66).  
 
Hic-5/ARA55 was isolated by yeast two hybrid analyses as a nuclear receptor 
coactivator, specifically binding the τ2 transactivation domain of GR located in its hinge 
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region (45).  However, the Hic-5/ARA55 interacting domain for AR has only been 
broadly localized to its ligand binding domain (46).  Although the association of Hic-
5/ARA55 with AR and GR has been well established, the nature of their interaction and 
specifically in which compartment it occurs and how it affects nuclear-receptor-mediated 
gene expression is not clear.  Furthermore, redistribution of Hic-5/ARA55 to the nucleus 
in response to hormone treatment has not been detected (unpublished results).   
 
Nuclear Receptor Corepressors 
 
Along with coactivators, another set of nuclear receptor interacting proteins has recently 
been identified termed corepressors, including both nuclear receptor corepressor (NCoR) 
and silencing mediator or retinoid and thyroid receptors (SMRT) (70, 71).  Corepressors 
repress nuclear receptor-mediated gene expression in the absence of ligand or presence of 
antagonist by interacting with histone deacetylases (HDACs) that in turn modify 
chromatin by removing acetyl groups on histone tails thereby promoting a closed 
chromatin structure, repressing transcription (24).   
 
Individually, coactivators induce and corepressors repress nuclear receptor-mediated 
gene expression (Figure 3).  However, most cells express a combination of both 
corepressors and coactivators that also interact with each other.  For example, RAC3 
interacts with NCoR, modifying thyroid hormone receptor (TR) regulated transcription 
(72).  An equilibrium model hypothesizes that it is not the absolute amount of coregulator 
expression but the ratio of corepressors versus coactivators that determines the extent of 
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nuclear receptor-mediated gene expression (73).  For example, overexpression of SMRT 
antagonizes TIF-2 coactivation of GR-mediated gene expression (74).  Because 
coactivators and corepressors, collectively referred to as coregulators, alter nuclear 
receptor-mediated gene expression in endocrine target tissues, their activity and 
expression along with various nuclear receptors, including AR and ER, in prostate as well 

















Figure 3.  Coregulator exchange on nuclear receptor-regulated genes.   
In the absence of hormone, a corepressor complex is associated with hormone 
responsive promoters, maintaining a closed chromatin state.  Upon hormone stimulation, 
the corepressor complex is replaced with ligand-bound nuclear receptors as well as a 




 AR and Prostate Tumor Development 
 
Changes in androgen function are linked to the development and progression of prostate 
cancer (PCa).  In fact, androgen-regulated gene products, such as PSA, are used as a 
marker of tumor progression and responsiveness to therapy (75, 76).  As previously 
mentioned PSA is produced by the epithelial cells and secreted into the seminal fluid.  
Normally, the basement membrane acts as a barrier to block PSA from escaping into 
systemic circulation. However, disruption of the basement membrane in PCa, results in a 
significant increase in serum PSA.   
 
Due to the androgenic dependence of prostate growth and survival, surgical and chemical 
castration has been used for more than sixty years as treatment for PCa.  Huggins et al. 
reported that castration significantly reduced levels of prostate acid phosphatase, an 
androgen-regulated gene product, also used as a tumor marker in patients with PCa, 
indicating the androgenic dependence of these tumors (77).  Since then, androgen 
ablation therapy including, orchiectomy and flutamide or bicalutamide anti-androgen 
treatment, which interfere with androgen binding to AR, has been the primary treatment 
for metastatic PCa (78, 79).  Androgen ablation therapy leads to temporary remission of 
most PCa, but most tumors eventually regress into an androgen independent or hormone 




 Reactive Stroma 
 
Although the epithelia compartment is the source of tumor cells, growth factor and 
cytokine secretion from both compartments of the prostate is altered in tumor 
development.  In fact, development of an altered stromal microenvironment, termed 
reactive stroma, carcinoma associated fibroblasts (CAF) or tumor stroma, enhances tumor 
cell survival, cellular proliferation, and migration (Figure 4, 81, 82).  Reactive stroma is 
characterized by the presence of undifferentiated myofibroblast cells that express both 
smooth muscle cell and fibroblasts markers (83).  Myofibroblasts are commonly found at 
areas undergoing tissue remodeling, producing ECM such as collagen I and fibronectin as 
well as proteases, including matrix metalloproteinases (MMPs) (84-86).  Although the 
process by which normal stroma converts to reactive stroma phenotype is unknown, 
differential epithelial-stromal interactions during carcinogenesis may result in the 
inability of neoplastic epithelium to maintain a differentiated stromal compartment (87).  
Furthermore, TGF-β may be involved in the progression to a reactive stroma phenotype 
by inducing myofibroblast formation (83).     
 
Data indicate that normal stroma cannot support tumor growth.  Using the Dunning rat 
prostate andenocarcinoma model, Hayashi and Cunha grafted fragments of tumorigenic 
tissue into normal mesenchyme located under the renal capsule (11).  After one month, 
not only did the tumor tissue’s growth rate decrease, but the cells also adopted the normal 
morphology of tall columnar secretory epithelium.  Alternatively, reactive stroma can 
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induce initiated, non-tumorigenic epithelial cells to form prostate tumors whereas normal 
stromal cells failed to promote tumor formation (88). 
 
To date, the exact mechanism by which reactive stroma influences the development of 
prostate tumors is unclear.  However, data indicate altered gene expression of growth 
factors such as KGF, FGF-2, TGF-β, and IL-6, matrix metalloproteinases (MMPs), and 
extracellular matrix in reactive stromal cells (22, 89-92).  The differential gene 
expression pattern induced by the reactive stroma may confer resistance to cell cycle 
inhibitors or metastatic properties to neighboring cells.   
 
Extracellular Matrix Remodeling in PCa 
 
Along with changes in reactive stromal-associated cells, alterations in the composition of 
the ECM associated with prostate tumors occur also.  For example, myofibroblasts 
produce ECM such as collagen I and fibronectin, resulting in increased expression of 
these ECM components in reactive stromal microenvironment (83, 85, 86, 93).  In 
addition to differential ECM production, myofibroblasts also synthesize various 
proteinases that aid in ECM remodeling within reactive stroma (84). 
 
ECM remodeling in PCa may disrupt cell adhesion as well as promote cellular invasion.  
For example, addition of fibronectin, which mediates cell adhesion, induced invasion of 
DU145 prostate cancer cells through basement membranes (94).  Also, a MMP inhibitor, 
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A-177430, reduced tumor growth, angiogenesis, and metastasis, indicating that ECM 












Figure 4.  Transition of normal epithelial-stromal homeostasis to carcinoma-reactive 
stroma interactions in PCa.  Normal epithelial-stromal interactions are disrupted during 
PCa progression.  While the epithelial compartment, the source of the carcinoma cells, 
undergoes significant changes in PCa, the stromal compartment, termed reactive stroma, 
as well as the surrounding ECM changes in PCa as well.  Normal stroma is mainly 
comprised of fibroblasts as well as smooth muscle cells.  The presence of myofibroblasts, 
which express both smooth muscle cell and fibroblasts markers, as well as tumor 
associated macrophages (TAM) results in differential growth factor, cytokine, and ECM 




Hormone Refractory Prostate Cancer 
 
Despite the initial remission of most PCa upon androgen ablation therapy, most tumors 
eventually regress into an androgen independent or hormone refractory tissue, capable of 
metastasis (80).  The mechanism by which PCa develops into an androgen independent 
state is not known.  However, AR expression is maintained in androgen independent 
tissue and may play a role in continued prostate survival during the androgen-
independent state (96).  For example, disrupting AR activity by addition of an AR 
binding antibody or an AR mRNA hammerhead ribozyme effectively inhibited 
proliferation of androgen-independent prostate cancer cells (97).   
 
Although the mechanisms by which AR is activated post androgen ablation therapy in 
androgen independent prostate cancer is unclear, several theories have emerged (1). The 
prostate may develop a capacity to increase its sensitivity to low levels of androgen 
through amplification of AR gene expression, increased AR stability, or enhanced AR 
nuclear localization (98, 99).  For example, elevated AR expression may be necessary for 
PCa progression to an androgen-independent state (100).  Furthermore, increased AR 
expression correlates with a higher probability of recurrence (101).  (2) In some cases, the 
AR is mutated within its LBD, resulting in its activation by other steroid hormones, such 
as estrogen, progesterone, and glucocorticoids (102).  However, the frequency of this 
mutation in patients is rather low (103).  (3) Altered secretion of autocrine or paracrine 
factors may account for prostate cellular proliferation and AR activity in the absence of 
androgens.  Altered growth factor secretion has not only been implicated in the reactive 
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stroma phenotype and subsequent tumor support, but also has been reported to increase 
AR activity in a ligand independent manner, promoting androgen independent prostate 
cancer growth.  For example, IGF-1, EGF, KGF and IL-6 treatment of LNCaP cells 
induced PSA expression by AR in the absence of androgen (104, 105).  (4) Altered 
expression of coactivators may enhance ligand-independent AR activity or increase 
androgen responsiveness in androgen independent prostate cancer.  Furthermore, 
transient overexpression of TIF-2 in CV-1 cells enhanced AR-mediated MMTV reporter 
activity in response to estradiol as well as progesterone (106).   
 
AIB 1 (amplified in breast 1)/ACTR/SRC-3/RAC3 is a nuclear receptor coactivator 
whose expression is amplified in 10% of primary breast tumor biopsies (107).  Many 
investigators have subsequently examined whether altered expression, activity, or 
mutation of other nuclear receptor coactivators are associated with tumors of different 
stages (107-109).  Analysis of coactivator expression in prostate cancer has yielded 
variable results.  For example, Gregory et al. report increased SRC-1 and TIF-2 
expression in prostate tumors whereas Fujimoto et al. report similar SRC-1 expression in 
benign, intermediate, and high grade cancers (106, 110).  Interestingly, Hic-5/ARA55 
expression was reduced in tumor as compared to normal tissue and Hic-5/ARA55 mRNA 
levels were lower in hormone-refractory PCa than that of previously untreated PCa 
(111,112)).  However, the effect of decreased Hic-5/ARA55 expression on AR-mediated 




SPECIFIC AIMS AND RATIONALE 
 
Aim 1.  Determining the mechanism by which Hic-5/ARA55 functions as a 
coactivator for nuclear receptors. 
Because Hic-5/ARA55 does not possess an obvious catalytic domain that is responsible 
for its coactivation properties, its mechanism of coregulator function has remained 
largely undefined.  At focal adhesion complexes, Hic-5/ARA55 serves as an adapter 
protein, coordinating multiple protein-protein interactions.  Therefore, it may serve as an 
adaptor molecule, either recruiting or stabilizing promoter-specific protein complexes by 
interacting with multiple coactivator proteins, coordinating their association with nuclear 
receptors at hormone responsive promoters.   
 
The overall goal of this aim was to determine if Hic-5/ARA55 interacts with nuclear 
receptors as well as other coregulators in a chromatin context.  Interaction studies 
preformed thus far have used yeast two hybrid analyses and in vitro pull down assays (45, 
46).  Here, we attempted to isolate GR and Hic-5/ARA55 in association with a known 
GR-responsive promoter, the mouse mammary tumor virus (MMTV) as well as 
endogenous p21 and c-fos gene promoters, using chromatin immunoprecipitation (ChIP) 
analysis (Figure 5).  Furthermore, the requirement of Hic-5/ARA55 for GR activity and 
promoter recruitment of coactivators was analyzed using RNA interference (RNAi) 
analysis.  The results from this aim indicate that Hic-5/ARA55 is associated to hormone-
responsive promoters in the absence and presence of glucocorticoids along with other 
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well-characterized coregulator proteins.  Furthermore, reduced expression of Hic-
5/ARA55 results in altered coactivator recruitment to target promoters.     
 
Aim 2.  Determining Hic-5/ARA55 expression and function in the prostate. 
In the prostate, AR activity appears critical for tumor development and/or progression 
(96, 97, 106).  Because Hic-5/ARA55 potentiates androgen receptor (AR)-mediated gene 
expression, its expression patterns in prostate cancer cell lines and tissue has been 
examined.  In normal prostates, Hic-5/ARA55 expression was restricted to the stromal 
compartment, and Hic-5/ARA55 mRNA levels were lower in hormone-refractory PCa 
than that of previously untreated PCa (111).  Because most analyses of coactivator 
expression in PCa progression use quantitative PCR, it is difficult to ascertain whether 
quantitative PCR results of Hic-5/ARA55 expression represents reduced expression of 
Hic-5/ARA55 within individual cells or alterations in the balance between 
stromal/epithelial cell content in tumors.   
 
The overall goal of this aim was to determine Hic-5/ARA55 expression levels in normal 
and tumor-derived prostates along with examining Hic-5/ARA55 coactivator function in 
the prostate.  Using immunohistochemistry analysis, Hic-5/ARA55 expression was found 
to be confined primarily to the stromal compartment in the prostate.  I therefore 
employed a prostate stromal cell line, WPMY-1 cells, and determined that Hic-5/ARA55 
was recruited along with AR to the androgen-responsive KGF promoter.  Furthermore, 
the responsiveness of KGF to androgen stimulation was lost after Hic-5/ARA55 
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expression was partially silenced using RNAi.  These results indicate that Hic-5/ARA55 
serves as a stromal-specific AR coactivator in the prostate.     
 
Aim 3.  Determining the effects of extracellular matrix signaling on GR-mediated 
transcription. 
Integrins, a family of membrane receptors located at focal adhesion complexes, bind 
specific ECM components, activating intracellular signaling cascades that influence cell 
migration, proliferation, and apoptosis.  Furthermore, ECM also influences nuclear 
receptor activity, resulting in differential cell growth and/or gene expression.  Malignant 
mammary cells grown on a laminin-rich basement membrane displayed greater ERα 
activity and express higher levels of ERα (6).  Although cross-talk between ER and ECM 
signaling has been reported, the mechanism by which ECM influences nuclear receptor-
mediated gene expression is unclear (6).   
 
Because Hic-5/ARA55 modulates focal adhesion complex signaling as well as 
functioning as a nuclear receptor coactivator, I analyzed the role of Hic-5/ARA55 in 
mediating GR responses to various ECM.  In this aim, I first determined the effects of 
ECM signaling on GR-mediated gene expression.  Matrigel decreased GR activity by 
decreasing GR protein levels.  Alternatively, fibronectin enhanced GR-mediated gene 
expression without effecting GR and Hic-5/ARA55 expression, subcellular localization, 
and DNA binding.  These results indicate that ECM does influence GR activity although 





































Figure 5.  Chromatin Immunoprecipitation (ChIP) Assay.  After the cells are 
stimulated for 1 hour with hormone to allow nuclear receptor translocation to the 
nucleus and promoter recruitment, the cells are crosslinked with formaldehyde to 
preserve nuclear receptor-DNA interactions.  After shearing the chromatin to 500-
2000 base pair fragments, the resulting chromatin is immunoprecipitated using nuclear 
receptor specific antibodies as well as non-specific antibody controls (IgG).  After the 
immune complex is isolated using protein A and G sepharose, the crosslinks are 
reversed and the proteins are removed by protease digestion.  The DNA is purified and 




CHAPTER 2  MATERIALS AND METHODS 
 
Antibodies, Plasmids, and Reagents – Antibodies used in this study included:  anti-GR 
(Affinity Bioreagents, Inc., Golden, CO); anti-Hic-5/ARA55 (BD Transduction Labs, Los 
Angeles, CA); anti-Glyceraldehyde 3-phosphate dehydrogenase (GAPDH CSA-335 
Stressgen Victoria, British Columbia, Canada); anti-NCoR (06-892 Upstate, 
Charlottesville, VA); anti-GR (H-300); anti-AR (N-20 ); anti-p300 (C-20); anti-SRC-1 
(M 341); anti-TIF-2 (M 343) (all from Santa Cruz Biotechnology, Santa Cruz, CA); anti-
phospho AKT; anti-AKT; anti-phosphoERK; anti-ERK (all from Cell Signaling 
Technology, Beverly, MA).  Plasmids used in this study included: an androgen 
responsive MMTV-luciferase reporter, pLC-Luc, as well as the Renilla-luciferase control.  
Cell signaling inhibitors used in this study include: U0126 and LY294002 (both from 
CalBiochem, SanDiego, CA) 
 
Cell Culture and Transient Transfection-  The A1-2 cells were derived from the T47D 
human mammary carcinoma cells line by stable transfection with pGRneo and MMTV-
LTR-luc plasmids as previously described (113).  Thus, these cells contain exogenous 
copies of stably integrated rat GR and a glucocorticoid-responsive luciferase reporter.  
The A1-2 cells were routinely maintained in modified Eagle’s medium at 37 C under 5% 
CO2.  The media was supplemented with 100 μg/ml penicillin-streptomycin, 10% FBS, 
10 mM HEPES, 2 mM glutamine, and 160 μg/ml G418.  WPMY-1 cells were routinely 
maintained in Dulbecco’s Modified Eagle’s Medium (Gibco, Grand Island, NY) 
supplemented with 100 μg/ml penicillin-streptomycin and 5% fetal bovine serum (FBS) 
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at 37 C under 5% CO2.  The WPMY-1 cells were isolated from a normal human prostate 
specimen and immortalized using SV40 large-T-antigen (114).  A1-2 cells were seeded 
on 12-well cell culture dishes at a density of 1.5 × 105 cells/ well for 24 h prior to 
transfection.  WPMY-1 cells were seeded on 12-well cell culture dishes at a density of 
7.5 × 104 cells/ well for 24 h prior to transfection.  Transfections were performed using 
Opti-MEM (Gibco, Grand Island, NY) and Lipofectamine transfection reagent 
(Invitrogen Technology, Carlsbad, CA) according to manufacturer’s instructions.  After 3 
h, fresh medium was added to the cells and hormone treatments were initiated where 
relevant.   
 
Extracellular matrix application to tissue culture plates – Cell culture plates were first 
coated with nitrocellulose that was dissolved in methanol (115).  After the nitrocellulose 
was applied, various ECM was diluted in PBS and incubated at room temperature for 1 
hour.  The ECM examined included:  vitronectin (Gibco BRL Life Technology, Carlsbad, 
CA), fibronectin (BD Biosciences, Bedford, MA), laminin mix (kind gift from Marcia 
Lewis, University of Pittsburgh), and growth factor reduced matrigel (BD Biosciences, 
Bedford, MA).  After the plates were washed with PBS, the A1-2 cells were plated.   
 
Western Blot Analysis- Cell lysates were collected in RIPA buffer (10 mM Tris, pH 8, 1 
mM EDTA, 0.5 mM EGTA, 140 mM NaCl, 1% Triton X-100, 0.1% Deoxycholic acid, 
0.1% SDS, 1 mM PMSF, and protease inhibitors) and were boiled in Sample Buffer (62.5 
mM Tris, pH 6.8, 2% SDS, 10% Glycerol, 5% 2-Mercaptoethanol, 0.001% Bromophenol 
Blue) for 5 min.  Proteins were then separated on 7.5% SDS-PAGE and transferred to 
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PVDF transfer membrane (Bio-Rad, Hercules, CA) in transfer buffer (20% methanol, 48 
mM Tris, 39 mM glycine, and 1.3 mM SDS) at 15 V for 30 min.  Membranes were then 
incubated in blocking buffer (5% dry milk in Tris-buffered saline, pH 7.4) for 2 h to 
overnight.  Next, the membranes were incubated with the indicated antibodies diluted 
1:1000 in blocking solution for 2 h at room temperature.  After extensive washing, the 
membranes were then probed with horseradish peroxidase-conjugated goat anti-mouse 
IgG antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) diluted in blocking solution 
for 1 h.  Finally, the membranes were washed and developed using the Renaissance 
Western Bolt Chemiluminescence Reagent (PerkinElmer, Wellesley, MA) according to 
the manufacturer’s instructions.  The membranes were stripped with Re-Blot Plus Strong 
Solution following the manufacturer’s instructions (Chemicon International, Temecula, 
CA) and reprobed for GAPDH as a loading control. Where indicated, quantification of 
scanned images was performed using the NIH Image software. 
 
RNAi-  RNAi plasmids were constructed following the manufacturer’s guidelines 
(pSilencer 2.1-U6 hygro, Ambion, Austin, TX).  The DNA template sequences for human 
Hic-5/ARA55 were RNAi-A 5’-GGAGGACCAGTCTGAAGAT-3’, RNAi-B 5’-
GAAAAGACCCAGCCTCCCT-3’, RNAi-C 5’-GCATCACAGATGAAATCAT-3’and 
RNAi-D 5’-GTGGATTGCACACAGACAA-3’.  The oligos (2μg each) were annealed to 
form double-stranded DNA after incubation in DNA annealing solution (pSilencer kit) 
for 3 minutes at 90 C followed by 1 hour at 37 C.  The resulting double stranded DNA 
was then inserted into the pSilencer 2.1-U6 hygro plasmid using T4 DNA ligase (New 
England Biolabs, Ipswich, MA) for 4 hours at 25 C.  Positive clones were identified after 
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enzymatic digestion by HindIII and BamHI (New England Biolabs, Ipswich, MA), 
releasing the 65 base pair insert.  The GFP template sequence was used as a positive 
control during the plasmid construction and a negative control for transfection analyses. 
 
Luciferase Assays - Luciferase activity in cell-free lysates was measured using a Victor 
3 1420 Multilabel plate reader (PerkinElmer, Wellesley, MA).  Cells were washed with 
PBS and lysed in Reporter Lysis Buffer (Promega, Madison, WI) followed by a freeze 
and thaw incubation to ensure proper cell lysis.  The lysate (25 μl) was incubated with 
luciferase assay reagent followed by a 10 sec relative luciferase unit measurement.  
Luciferase activity was normalized to Renilla luciferase activity according to 
manufacturer’s instructions.  All experiments were performed three or more times. 
 
Chromatin Immunoprecipitation – A1-2 or WPMY-1 cells were grown on 15 cm 
plates to 80-90% confluence in medium supplemented with charcoal dextran treated FBS 
for 24 hours.  The cells were treated with EtOH-vehicle, 100 nM Dex, or 10 nM 
Mibilerone (Mib) for 1 h and crosslinked by addition of formaldehyde (1% final) to the 
medium for 30 min at room temperature.  After the crosslinking reaction was stopped by 
addition of 0.1 volume of 1.4 M glycine, the cells were washed with PBS, scraped into 
ice-cold PBS, and centrifuged at 3000 RPM for 5 minutes at 4 C.  The cells were lysed 
and the nuclei collected by resuspending the pellet in 2 ml of cold ChroIP Buffer (50mM 
HEPES, KOH pH 8, 1mM EDTA, pH 8, 0.5mM EGTA, pH 8, 140mM NaCl, 10% 
glycerol, 0.5% IGEPAL, 0.25% Triton X-100, and 1mM PMSF) for 10 minutes and 
centrifuged at 3000 RPM for 5 minutes at 4 C.  The pellet was resuspended in 2 ml of 
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cold Wash Buffer (10mM Tris-HCl, pH 8, 1mM EDTA, pH 8, 0.5mM EGTA, pH 8, 
200mM NaCl, and 1mM PMSF) for 10 minutes at 4 C followed by centrifugation at 3000 
RPM for 5 minutes at 4 C.  The pellet was resuspended in 2 ml of ice-cold RIPA Buffer 
(10mM Tris-HCl, pH 8, 1mM EDTA, pH 8, 0.5mM EGTA, pH 8, 140mM NaCl, 1% 
Triton X-100, 0.1% Na-deoxycholate, 0.1% SDS, 1mM PMSF, and protease inhibitor 
cocktail) for 10 minutes at 4 C followed by centrifugation at 3000 RPM for 5 minutes.  
The isolated nuclei were then sonicated using a water bath sonicator for three minutes 
(Misonix Sonicator with Cuphorn, Farmingdale, NY, Output at 6, Processing time 3 
minutes, Pulse on 10 sec, Pulse off 15 sec) to produce fragments 500-2000 base pair in 
size as previously described (30).  Chromatin fragments were precleared for 1-4 h at 4C 
using 50 μl of protein A and G sepharose containing salmon sperm DNA (Upstate, Lake 
Placid, NY) to reduce nonspecific binding followed by centrifugation at 3000 RPM for 5 
minutes at 4 C.  Next, 1-10% of the sheared chromatin was removed to use as input 
samples later.  The chromatin fragments were diluted with RIPA buffer (1 ml/IP), 
separated into 2 to 4 IPs, and immunoprecipitated with specific antibodies (1 μg/ IP) 
overnight at 4 C.  After immunoprecipitation, 30 μl of protein A and G sepharose 
(Upstate, Lake Placid, NY) was added and the incubation was continued for 1 h.  The IPs 
were washed twice with RIPA buffer, twice with RIPA buffer +500 mM NaCl, and once 
with LiCl buffer (10mM Tris-HCl, pH 8, 1mM EDTA, pH 8, 0.5mM EGTA, pH 8, 
250mM LiCl, 1% Triton X-100, 1% Na-deoxycholate, and 1mM PMSF).   The 
precipitates were eluted with 100 μl of freshly made reverse cross-linking buffer (1% 
SDS and 0.1 M NaHCO3), adding 4 μl of 5 M NaCl at 65 C for 4 h.  The Input samples 
were reversed by diluting 10μl Input into 190 μl ChIP Dilution Buffer (0.01% SDS 1.1% 
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Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl, pH8, and 167mM NaCl) adding 8 μl of 
5M NaCl/tube also for 4 hr at 65 C.  The proteins were removed by addition of proteinase 
K (2 μl/sample, Roche, Mannheim, Germany, 20 mg/ml) for 1 h at 45 C.  DNA was 
isolated using the QIAquick PCR purification kit (Quiagen, Valencia, CA).  
Thermocycling conditions involved an initial denaturation step at 95 C for 12 min 
followed by 28-32 cycles at 95 C for 30 sec and 56 C for 30 sec and 72 C for 30 sec.  
Primers for the MMTV promoter were: forward primer 5’-
GCGGTTCCCAGGGCTTAAGT-3’ and reverse primer 5’-
CCATTTTACCAACAGTACCG-3’.  Primers for the c-fos promoter were: forward 
primer 5’-TCCCAGCAGTCGAGGTATTC-3’ and reverse primer 5’-
GGTCAGTTCGGGATGACAAG-3’.  Primers for the p21 promoter were: forward 
primer 5’-GGTGTCTAGGTGCTCCAGGT-3’ and reverse primer 5’-
GCACTCTCCAGGAGGACACA-3’.  Primers for the KGF promoter were: forward 
primer 5’-CCCTTTCCCCTTCTAACTGC-3’ and reverse primer 5’-
ACCTTTGCTGACCTCATTGG-3’.  Primers for the luciferase gene were:  forward 
primer 5’-CCAGGGATTTCAGTCGATGT-3’ and reverse primer 5’-
AATCTGACGCAGGCAGTTCT-3’.  PCR products were resolved on a 12% 
polyacrylamide gel and visualized with ethidium bromide.  Semi-quantitation was done 
using densitometric analysis of the resolved gels using the Kodak Imaging System.  Data 
points were subtracted for background and normalized to the Input data.  
 
For sequential ChIPs, complexes immunoprecipitated with either anti-GR or anti-Hic-
5/ARA55 antibodies (3 μg/ IP) were eluted by incubation with 100 μl of 10 mM DTT for 
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30 min at 37 C.  After centrifuging the eluted IPs for 10 minutes at 3000 RPM 4C, they 
were diluted 1:50 in ChIP Dilution Buffer (20 mM Tris-HCl, pH 8.1, 2mM EDTA, 150 
mM NaCl, 1% Triton X-100), followed by reimmunoprecipitation with either isotype 
control Ab, anti-Hic-5, or various coactivators or corepressor antibodies (1 μg/ IP).   
 
Reverse Transcriptase PCR - Total RNA was isolated from A1-2 and WPMY-1 cells 
using the RNAqueous RNA isolation kit (Ambion, Austin, TX) following the 
manufacturer’s instructions.  For RT-PCR, 1 μg of RNA was incubated with 100 μl of 
reaction mix containing 25 mM MgCl2, 25 mM dNTPs (PerkinElmer), 10X PCR II 
Buffer (Gibco BRL), 40 U/μl RNAsin RNase inhibitor (Promega), 45 μM random 
hexamers (IDT, Coralville, IA), 200 U/μl Superscript reverse transcriptase (Gibco), and 
nuclease free water (Ambion).  Parallel reactions were performed without reverse 
transcriptase to control for the presence of contaminant DNA.  The samples were 
incubated at 25 C for 10 min, at 48 C for 30 min, and at 95 C for 5 min followed by 4 C 
for 5 min to inactivate the reverse transcriptase. 
 
For amplification, a PCR reaction containing a cDNA aliquot along with AmpliTaq Gold 
DNA polymerase in a volume of 25 μl was used according to the manufacturer’s 
instructions (Applied Biosystems, Foster City, CA).  Primers used for gene expression 
analysis were: c-fos:  forward primer 5’-TGCCAACTTCATTCCCACGGT-3’ and 
reverse primer 5’-TAGTTGGTCTGTCTCCGCTTG-3’; p21:  forward primer 5’- 
GCGACTGTGATGCGCTAATGG-3’ and reverse primer 5’-
TCCCAACTCATCCCGGCCTC-3’; KGF: forward primer 5’- 
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CAATCTAGAATTCACAGATAGGAGGAGGC -3’ and reverse primer 5’-
ACAATTCCAACTGCCACTGTCCTGATTTC-3; GAPDH: forward primer 5’-
CATCACCATCTTCCAGGAGCGAGA-3’ and reverse primer 5’-
GTCTTCTGGGTGGCAGTGATGG-3’.  Thermocycling conditions involved an initial 
denaturation step at 95 C for 12 min followed by 28-30 cycles at 95 C for 30 sec and 56 
C for 30 sec and 72 C for 30 sec.  Specific PCR amplification products were separated on 
a 12% PAGE and detected by EtBr staining.  Experiments were performed with 
duplicates for each data point.  
Immunofluorescence – WPMY-1 cells were cultured on glass coverslips treated with 
EtOH-vehicle or 100 nM Leptomysin B (LC Laboratory, Woburn, MA) for 1 hour, fixed 
with 4% paraformaldehyde in PBS for 30 minutes at 4°C, washed with PBS and 
permeabilized in PBS containing 1% BSA and 0.5% Triton X-100 for 5 minutes at room 
temperature.  The cells were incubated overnight at 4 C with anti-Hic-5/ARA55 specific 
antibodies diluted 1:1000 in PBS.  After extensive washing with PBS, the cells were 
incubated 2 hours at room temperature with anti-mouse IgG-Cy2 conjugated antibodies 
(Molecular Probes, Portland, OR) diluted 1:300 in PBS.  Nuclei were stained with DAPI 
(10 μg/ml, Molecular Probes, Carlsbad, CA) according to manufacturer’s instructions.  
 
Immunohistochemistry – Paraffin-embedded prostate tissue sections were obtained 
from the Shadyside Hospital Tissue Bank.  Tissue sections were deparaffinized, 
rehydrated, and antigens retrieved by boiling in 10 mM citrate buffer, pH 5.5 for 10 
minutes.  The sections were incubated overnight at 4 C in a humid chamber with anti-
Hic-5/ARA55 antibodies diluted 1:2000 in PBS.  Immunostaining was performed using a 
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Vecta stain kit (Vector Laboratories Inc., Burlingame, CA) following manufacturer’s 
instructions.  Normal mouse IgG was used as controls.     
 
Statistics 
Comparisons of two mean values were performed using a paired t test.  p values of < 0.05 
were taken to be significant and all data were analyzed using GraphPad Prism 3.00 


















CHAPTER 3  Determining the mechanism by which Hic-5/ARA55 functions as a 
coactivator for nuclear receptors. 
 
HYPOTHESIS: 
Because Hic-5/ARA serves as an adapter protein at focal adhesion complexes 
coordinating multiple protein-protein interactions, it serves as nuclear receptor 
coactivator by interacting with multiple coactivator proteins, coordinating their 





Hic-5/ARA55 is associated primarily with focal adhesion complexes as well as localized 
within the nucleus (53).  At focal adhesion complexes, Hic-5/ARA55 as well as other 
group III LIM domain proteins link various intracellular signaling modules to plasma 
membrane receptors that respond to various extracellular signals including growth factors 
and the extracellular matrix (116, 117).  Furthermore, Hic-5/ARA55 was recently isolated 
as a nuclear receptor interacting protein that functions as a coactivator for nuclear 
receptor-mediated gene expression (45, 46, 66).  Reduced expression of Hic-5/ARA55 
resulted in decreased AR and PPARγ-mediated transactivation (46, 66).    
 
Because Hic-5/ARA55 does not possess an obvious catalytic domain that is responsible 
for its coactivation properties, its mechanism of coregulator function has remained 
undefined.  However, it may serve as an adaptor molecule, either recruiting or stabilizing 
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promoter-specific protein complexes.  LIM proteins are well recognized for their roles as 
molecular adaptors, functioning in stabilizing higher order protein complexes at focal 
adhesion complexes.  Within focal adhesion complexes, Hic-5/ARA55 as well as other 
group III LIM domain proteins link various intracellular signaling modules to plasma 
membrane receptors that respond to extracellular signals including growth factors and the 
extracellular matrix (116, 117).  For example, Hic-5/ARA55 and paxillin interact with 
multiple focal adhesion-associated proteins such as vinculin and focal adhesion kinase 
(FAK) (118).  
 
Here, we examined the mechanism of Hic-5/ARA55 action as a coactivator, focusing 
exclusively on endogenous Hic-5/ARA55 in the A1-2 derivative of T47D breast cancer 
cells and not relying on artificial enhancement of its nuclear localization.  Single and 
sequential ChIP assays revealed an association of Hic-5/ARA55 with GR and various 
coactivators on viral and cellular glucocorticoid-responsive promoters.  Furthermore, 
siRNA-mediated ablation experiments established Hic-5/ARA55 in maintaining the 
assembly of coactivator complexes required for efficient glucocorticoid-induced 
transcription.  Thus, Hic-5/ARA55 may function as a nuclear receptor coactivator as an 
adaptor protein, recruiting or stabilizing histone acetyltransferase-containing complexes 








Hic-5/ARA55 is localized to a glucocorticoid-responsive promoter.   
While an interaction between Hic-5/ARA55 and GR has been revealed in yeast two 
hybrid assays, the relevance of this association to the coactivator activity of Hic-
5/ARA55 towards GR is unknown (45, 46).  In order to determine the mechanism by 
which Hic-5/ARA55 serves as a GR coactivator, we assessed whether Hic-5/ARA55 was 
bound to the glucocorticoid responsive mouse mammary tumor virus (MMTV) promoter, 
using chromatin immunoprecipitation (ChIP) assays.  A1-2 cells, a T47D cell derivative 
that contains an integrated MMTV-luciferase gene, were grown in medium containing 
steroid depleted serum for 2 days before initiating hormone treatments.  Following a 1 h 
ethanol-vehicle or Dex (100nM) treatment, GR and Hic-5/ARA55 recruitment to the 
MMTV promoter was analyzed by ChIP analysis using antibodies specific for each 
(Figure 6).  As expected, there was a Dex-dependent localization of GR to the MMTV 
promoter, but not the coding region of the luciferase gene.  Hic-5/ARA55 was also 
recruited to the MMTV promoter in the presence of Dex.  These results provide the first 
demonstration of endogenous Hic-5/ARA55 binding to a specific promoter in vivo and 
the hormone-dependent recruitment of Hic-5/ARA55 to a nuclear receptor responsive 
promoter.  
 
GR and Hic-5/ARA55 co-occupy a glucocorticoid-responsive promoter in vivo.  To 
determine if GR and Hic-5/ARA55 are contained within a stable complex at GR- 
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Figure 6.  A.  Binding of Hic-5/ARA55 to the MMTV promoter.  Soluble chromatin 
was prepared from A1-2 cells treated with EtOH-vehicle or Dex (100 nM) for 1 h.  
Protein-bound DNA complexes were immunoprecipitated with antibodies against GR or 
Hic-5/ARA55.  After crosslink reversal, purified DNA was amplified with primers 
specific for the MMTV promoter (left panels) or the coding region of the luciferase gene 
(right panels).  PCR products in the Input panel were amplified using diluted chromatin 
that was not immunoprecipitated.  A rabbit IgG was used to detect any nonspecific 
immunoprecipitated DNA.  Gel shown of PCR products, resulting from 28 rounds of 
PCR amplification, is representative of three separate experiments.  B.  Relative changes 
in GR and Hic-5/ARA55 recruitment to the MMTV promoter were calculated based on 
semi-quantitative results from the original images.  Values represent percent of sample 
input after subtraction of IgG control ± SD for three separate experiments. *, P ‹ 0.05, 




Figure 7.  Co-occupancy of GR and Hic-5/ARA55 on the MMTV promoter.  Soluble 
chromatin was prepared as in Figure 1.  GR-bound DNA complexes were 
immunoprecipitated (indicated as 1st ChIP), eluted, and re-immunoprecipitated with GR 
and Hic-5/ARA55 specific antibodies.  After crosslink reversal, purified DNA was 
amplified with primers specific for the MMTV promoter.  PCR products in the Input panel 
were amplified using diluted chromatin that was not immunoprecipitated.  A rabbit IgG 
was used to detect any nonspecific immunoprecipitated DNA.  Gel shown of PCR 
products, resulting from 32 rounds of PCR amplification, is representative of two separate 





responsive promoters, we performed sequential immunoprecipitations followed by ChIP 
analysis (Figure 7).  A1-2 cells were grown and treated as in Figure 6 and the diluted  
chromatin was first immunoprecipitated using antibodies specific for GR.  After  
extensive washes, the precipitates were reimmunoprecipitated using antibodies specific 
for Hic-5/ARA55.  As shown in Figure 7, GR containing chromatin segments of the 
MMTV promoter also contain Hic-5/ARA55.  These data demonstrate that GR and Hic-
5/ARA55 can co-occupy the MMTV promoter in vivo and that this association is 
enhanced upon Dex treatment.  The sequential immunoprecipitation reduced the 
detection of GR in chromatin isolated from cells not treated with hormone.  However, 
Hic-5/ARA55 was still detected in MMTV chromatin isolated from untreated cells.  
Thus, Hic-5/ARA55 may play a role in both basal and hormone-regulated transcription 
from the MMTV promoter. 
 
GR and Hic-5/ARA55 associate with endogenous glucocorticoid-responsive 
promoters in vivo.  
To establish whether both GR and Hic-5/ARA55 are recruited to endogenous promoters, 
we initially performed RT-PCR analysis to identify endogenous glucocorticoid 
responsive genes in A1-2 cells.  Glucocorticoid induction of p21 expression has been 
demonstrated in A1-2 cells (119).  Although the mechanism responsible for hormone 
effects on p21 expression is not known, p21 may be a target of Hic-5/ARA55 action as 
overexpression or forced nuclear retention of Hic-5/ARA55 resulted in increased p21 and 





Figure 8.  Association of GR and Hic-5/ARA55 with the chromatin of endogenous 
promoters in vivo.  A.  Glucocorticoid responsive gene expression in A1-2 cells was 
analyzed by RT-PCR.  A1-2 cells were treated with EtOH-vehicle or Dex (100nM) for 10 
h.  RNA from A1-2 cells was isolated to determine the relative expression of p21, c-fos, 
and GAPDH mRNAs.  The reverse transcriptase reaction was carried out with 0.5 μg total 
RNA.  Parallel reactions performed without reverse transcriptase to control for the 
presence of contaminant DNA did not generate specific PCR products for any primers 
(data not shown).  The gel shown of PCR products, resulting from 28 rounds of PCR 
amplification, is representative of two separate experiments.  B.  Chromatin Re-IP 
analysis was performed as in Figure 2 using c-fos or p21 promoter-specific primers. The 
gels shown of PCR products, resulting from 32 rounds of PCR amplification, are 
representative of two separate experiments.   
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5/ARA55 played a role in glucocorticoid induction of these genes in A1-2 cells, we used 
ChIP assays to assess promoter occupancy of the p21 and c-fos genes. 
 
A1-2 cells were grown in medium containing charcoal dextran stripped FBS.  After 2 
days, the cells were treated with ethanol or 100nM Dex for 10 h followed by RT-PCR 
analysis.  As shown in Figure 8A, we confirmed using RT-PCR that both p21 and c-fos 
mRNAs were induced by Dex in A1-2 cells.  Furthermore, GR association with the c-fos 
and p21 promoters was enhanced by Dex treatment (Figure 8B).  Importantly, sequential 
ChIP experiments demonstrated that Hic-5/ARA55 was also a component of GR-
containing chromatin at these endogenous promoters.  Thus, endogenous Hic-5/ARA55 is 
included within GR complexes at the promoter of endogenous genes whose transcription 
is regulated by glucocorticoids.     
 
Reduced expression of Hic-5/ARA55 results in decreased GR transactivation.   
It has been established that overexpression of Hic-5/ARA55 increases GR-mediated 
transcription (45).  However, these types of experiments do not reveal whether 
endogenous Hic-5/ARA55 is necessary for GR activity.  Thus, we used a siRNA 
approach to ablate Hic-5/ARA55 expression in A1-2 cells and assess the impact on GR 
transactivation.  A1-2 cells were analyzed for Hic-5/ARA55 expression in A1-2 cells by 
Western blot analysis following transfection with either a control GFP siRNA or Hic-
5/ARA55 siRNA.  Densitometric analysis revealed that there was approximately 60% 
less Hic-5/ARA55 in cells transfected with the Hic-5/ARA55 siRNA as compared to 













































Figure 9.  Effects of RNAi-mediated silencing of Hic-5/ARA55 on GR transactivation.  
A.  A1-2 cells, cultured in 6 well plates, were transfected with 2 μg of GFP (negative 
control) or 2 μg human Hic-5/ARA55 RNAi constructs.  After 48 h, cells were harvested, 
lysed, and analyzed for Hic-5/ARA55, GR, and GAPDH protein levels by Western 
blotting. B.  A1-2 cells were transfected with RNAi constructs as in A.  After 48 h, the 
cells were treated with EtOH-vehicle or 1nM Dex for 24 h after which luciferase activity 
was measured.  Data shown are mean of three separate experiments.  C.  A1-2 cells were 
transfected as in A.  After 48 h, the cells were treated with 1nM Dex for 8 h.  RT-PCR 
reactions were then performed as in Fig. 3A.  The gel shown of PCR products, resulting 
from 28 rounds of PCR amplification, is representative of three separate experiments.  *, 
P ‹ 0.005, significantly different from the mean value of siGFP controls; bars, SD. 
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at reducing endogenous Hic-5/ARA55 expression.  Nonetheless, the reduction in Hic-
5/ARA55 expression in A1-2 cells by the most effective siRNA was sufficient to 
generate reduced GR transactivation, as measured by ligand-dependent luciferase 
expression (Figure 9B).  Furthermore, this reduction in GR activity was not due to 
decreased GR expression in siHic-5/ARA55-transfected cells (Figure 9A).  We also 
analyzed glucocorticoid-induced c-fos and p21 mRNA expression after transfection with 
Hic-5/ARA55 siRNA (Figure 9C).  Although there was no reduction in c-fos expression, 
there was a reduction in p21 expression upon silencing of Hic-5/ARA55.  Because the 
silencing of Hic-5/ARA55 expression was not completely effective, we can not conclude 
that Hic-5/ARA55 is essential for GR activity.  However, these results indicate that 
endogenous Hic-5/ARA55 contributes to optimal GR transactivation from a subset of 
promoters in A1-2 cells.   
 
Hic-5/ARA55 interaction with coactivators on GR responsive promoters.   
Because Hic-5/ARA55 does not possess HAT or methyltransferase activity, it may not 
modify histones directly.  However, Hic-5/ARA55 may be involved in recruiting other 
chromatin modifying coactivators.  To determine if Hic-5/ARA55 interacts with other 
coactivator proteins at glucocorticoid responsive promoters, we performed sequential 
ChIPs, first using antibodies specific for Hic-5/ARA55 followed by re-
immunoprecipitation with anti-SRC-1, anti-TIF-2, anti-RAC3, anti-CBP or anti-p300 
antibodies.  As shown in Figure 10, TIF-2, RAC3, CBP, and p300, but not SRC-1 were 
associated within Hic-5/ARA55-containing chromatin at the MMTV promoter in 
glucocorticoid treated A1-2 cells.   Interestingly, while TIF-2, RAC3, and CBP were  
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Figure 10.  Co-occupancy of Hic-5/ARA55 and coregulators on the MMTV and c-fos 
promoters in vivo.   Soluble chromatin was prepared as in Figure 1.  Hic-5-bound DNA 
complexes were immunoprecipitated, eluted, and re-immunoprecipitated with A and B, 
SRC-1, TIF-2, RAC3, CBP, p300, or C, NCoR specific antibodies.  After crosslink 
reversal, purified DNA was amplified using MMTV (A and C) or c-fos (B)-specific 
primers.  PCR products in the Input panel were amplified using diluted chromatin that was 
not immunoprecipitated.  The gels shown of PCR products, resulting from 28-32 rounds 
of PCR amplification, are representative of three separate experiments.    
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detected within Hic-5/ARA55-containing chromatin complexes at the c-fos promoter, 
neither p300 nor SRC-1 was detected in Hic-5/ARA55 chromatin complexes (Figure 
10B).  p300 is recruited to the c-fos promoter in response to glucocorticoids (Figure 10B), 
but must exist in a separate coactivator complex that does not include stably associated 
Hic-5/ARA55.  These results indicate that Hic-5/ARA55 is located within a complex of 
coactivator proteins at glucocorticoid responsive promoters and that recruitment of p300 
to Hic-5/ARA55-associated chromatin complexes may be promoter specific. 
 
Because Hic-5/ARA55 was present on the chromatin of glucocorticoid-responsive 
promoters in the absence of hormone stimulation, we analyzed its possible interaction 
with corepressor-containing complexes.  Using sequential ChIP, we first 
immunoprecipitated Hic-5/ARA55-containing complexes followed by re-
immunoprecipitation with NCoR-specific antibodies.  As shown in Figure 10C, the 
association of NCoR with Hic-5/ARA55 at the MMTV promoter is higher in cells not 
exposed to hormone.  Thus, Hic-5/ARA55 can be contained within both coactivator and 
corepressor complexes at an individual promoter. 
 
Reduced promoter recruitment of TIF-2 and p300 after silencing Hic-5/ARA55 
expression.   
Because Hic-5/ARA55 is made up of multiple protein interaction motifs, it may function 













Figure 11.  Coactivator recruitment on the MMTV promoter following ablation of Hic-
5/ARA55.  A1-2 cells were transfected as in Fig. 4. with vectors expressing siRNA for 
Hic-5/ARA55 or GFP.  After 72 hours, ChIP analysis was performed as in Fig.1.  After 
crosslink reversal, purified DNA was amplified with primers specific for the MMTV 
promoter.  Gel shown of PCR products, resulting from 28 rounds of PCR amplification, 







coregulator proteins or stabilizing the coactivator complex.  In order to assess the 
necessity of Hic-5/ARA55 in coactivator recruitment to glucocorticoid-responsive genes,  
we performed ChIP assays in cells after silencing Hic-5/ARA55 expression.  As shown in 
Figure 11, after ablation of Hic-5/ARA55 expression, TIF-2 and p300 recruitment to the 
MMTV promoter in response to glucocorticoids was reduced.  Interestingly, there was 
increased p300 recruitment in the absence of hormone upon silencing Hic-5/ARA55 
expression.  The corresponding reduction of GR transactivation (Figure 9) and 
coactivator recruitment (Figure 11) that results from partial Hic-5/ARA55 ablation 
demonstrates the critical role of Hic-5/ARA55 in maintaining the assembly of coactivator 





Here, we showed that endogenous Hic-5/ARA55 is recruited to both stably integrated 
viral and endogenous glucocorticoid-responsive promoters in response to hormone 
treatment.  Furthermore, GR and Hic-5/ARA55 co-occupied these promoters within 
stable complexes that can be recovered by sequential ChIPs.  We also demonstrated an 
association between Hic-5/ARA55 and coactivator-containing complexes at 
glucocorticoid-responsive promoters using sequential ChIPs.  Using gel shift assays and 
co-immunoprecipitations, Shibanuma et al. showed that Hic-5/ARA55 containing a 
heterologous nuclear localization signal (NLS) regulated p21 expression by interacting 
with Smad3, but not p300 or Sp1 directly in transfected cells (65).  While these results 
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imply that Hic-5/ARA55 association with p300 may be cell type- or promoter-specific, it 
may not be appropriate to compare the function of endogenous Hic-5/ARA55 in our case 
with transfected, overexpressed Hic-5/ARA55 that contains a heterologous NLS to force 
robust nuclear retention.  However, promoter-specific recruitment of p300 to endogenous 
Hic-5/ARA55 chromatin complexes was observed in A1-2 cells, corroborating the results 
obtained with exogenously introduced NLS-Hic-5/ARA55 constructs.   
 
Interestingly, for the promoter in which p300 in not a component of Hic-5/ARA55 
complexes (i.e. the c-fos promoter), partial ablation of Hic-5/ARA55 was not sufficient to 
impact glucocorticoid-regulated transcription.  While we cannot rule out the possibility 
that more complete ablation of Hic-5/ARA55 would hinder glucocorticoid-induced 
transcription from the c-fos promoter, Hic-5/ARA55 may only exert an essential function 
to maintain the stability of distinct subsets of coactivator complexes (i.e. p300-
containing).  Partial Hic-5/ARA55 ablation also blocked PPARγ-induced expression of a 
select set of epithelial-specific genes (66).  While the differential recruitment of 
coactivators was not examined in this case, these results highlight the importance of Hic-
5/ARA55 in impacting gene-specific effects of nuclear receptors.  
 
Although there have been no reports indicating a repressive function for Hic-5/ARA55 on 
nuclear receptor-mediated gene expression, ChIP analysis consistently revealed Hic-
5/ARA55 binding to the MMTV promoter in the absence of hormone.  The enhanced 
association of NCoR with Hic-5/ARA55 complexes at the MMTV promoter in non-
hormone treated cells suggests that Hic-5/ARA55 may in fact participate in maintaining 
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low basal levels of transcription from this promoter.  However, Hic-5/ARA55 was not 
essential for limiting MMTV transcription in the absence of hormone as its partial 
ablation does not lead to enhanced transcription.  Whereas we have observed enhanced 
basal transcription from a steroid hormone-regulated gene upon Hic-5/ARA55 ablation in 
a prostate cell line, definitive demonstration of Hic-5/ARA55 participation in 
transcriptional repression will require more thorough analysis. 
 
Finally, siRNA ablation experiments reported here establish that Hic-5/ARA55 is 
required for the stable association of p300 and TIF-2 with the MMTV promoter.  Thus, 
Hic-5/ARA55 may stabilize select protein complex formation at GR-responsive 














CHAPTER 4  Determining Hic-5/ARA55 expression and function in the prostate. 
 
Hypothesis 2  
Because Hic-5/ARA55 expression in the prostate is restricted to the stromal 
compartment, it modulates AR-mediated gene expression, products of which are required 




As previously mentioned, communication between the epithelial and stromal 
compartments of the prostate is crucial for the maintenance of prostate growth and 
function (7, 8).  Additionally, androgens along with functional AR expression in the 
stromal compartment are necessary for prostate development (14).  In the stromal 
compartment, AR regulates the expression of various growth factors such as KGF (FGF-
7), a member of the fibroblast growth factor family (14, 19-21).  KGF is exclusively 
expressed in the stromal compartment of the prostate while its receptor, a spliced variant 
of the FGF type 2 receptor (FGFR2IIIb), is expressed solely in the epithelial 
compartment (3).  These characteristics suggest that KGF is a paracrine mediator of 
signaling from the stroma to the epithelial compartment that can influence epithelial cell 
growth (1, 22). 
        
Along with prostate development, androgens are critical for PCa progression and may be 
involved in the transition to hormone refractory PCa (97).  AR activation in the absence 
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of circulating androgens in hormone refractory PCa is an area of intense investigation.  
Some reports suggest that signaling events issued by cytokines or growth factors such as, 
IGF-1, EGF, KGF and IL-6,  can induce AR-mediated gene expression in the absence of 
androgens (104, 105).  Furthermore, KGF expression is significantly increased in prostate 
cancer (22).  In addition to androgen independent activation of AR, increased expression 
of coactivators in PCa cell lines have enhanced AR responsiveness to low levels of 
androgen, anti-androgens, and other steroid hormones such as estrogen or progesterone 
(44, 106).  
 
In the prostate, Hic-5/ARA55 expression was restricted to the stromal compartment 
(111).  Interestingly, Hic-5/ARA55 expression was reduced in tumor as compared to 
normal tissue (112).  Furthermore, Hic-5 mRNA levels were lower in hormone-refractory 
PC than that of previously untreated PCa, and in recurrent hormone refractory PCa, 
higher Hic-5/ARA55 expression correlated with unfavorable recurrence-free survival as 
well as overall survival (122).  Because most analyses of coactivator expression in PCa 
uses quantitative PCR, it is difficult to ascertain whether this represents reduced 
expression of Hic-5/ARA55 within individual cells or alterations in the balance between 
stromal/epithelial cell content in tumors. 
 
In this study, we examined Hic-5/ARA55 expression and activity in the prostate.  In both 
normal and tumor derived prostates, Hic-5/ARA55 expression is confined to the stromal 
compartment.  We therefore focused our analysis of Hic-5/ARA55 function in a prostate 
stromal, myofibroblast cell line, WPMY-1 cells.  We show here that Hic-5/ARA55 
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functions as an AR coactivator in WPMY-1 cells and is necessary for effective androgen 





Regional expression of Hic-5/ARA55 in human prostate tissue.   
Given Hic-5/ARA55 effects on AR and its role in hormone-dependent growth of prostate 
cancer (PCa) cell lines, a number of studies have examined its expression in prostate 
tissue.  For example, Hic-5/ARA55 mRNA expression, as quantified using PCR, is 
reduced in hormone refractory prostate cancer tissue (HRPC) as compared to normal or 
benign prostatic hypertrophy (BPH) tissue (112, 122).  Since these tissue samples 
contained a heterogeneous population of cells, potential cell type specific differences in 
Hic-5/ARA55 expression would not be revealed.  Therefore, we analyzed prostate tissue 
from both normal human donors and prostate cancer patients for Hic-5/ARA55 
expression using immunohistochemistry.  As shown in Figure 12 (top panels), Hic-
5/ARA55 expression is confined to the stromal compartment of the prostate.  The 
epithelial compartment was consistently negative for Hic-5/ARA55 expression.  This 
profile of Hic-5/ARA55 expression in the prostate is consistent with those previously 
published using normal human prostates (111).  In tumor-derived prostate tissue, Hic-
5/ARA55 was also restricted to stromal cells and not detected in the prostate tumor cells 
(Figure 12, bottom panels).  In both cases, the Hic-5/ARA55 staining appeared diffuse 






Figure 12.  Hic-5/ARA55 expression in human prostate tissue sections.  Normal human 
prostate tissue sections from donor prostates (A and B) or from PCa patients (C and D) 
were stained with a non-immune antibody control (A and C) or an anti-Hic-5/ARA55-
specific antibody (B and D).  Original magnification X66.  Compartments of the 




Nucleocytoplasmic shuttling of Hic-5/ARA55 in the WPMY-1 prostate stromal cell 
line.   
Hic-5/ARA55 coactivator function has been analyzed in a variety of epithelial-derived 
PCa cell lines, including LNCaP, PC3, and DU145 cells (46).  However, because its 
expression is confined to the stromal compartment of the prostate, PCa cell lines may not 
provide a suitable model system with which to analyze Hic-5/ARA55 activity.  Given the 
apparent stromal expression of Hic-5/ARA55, we considered it more appropriate to 
examine Hic-5/ARA55 effects on AR in stromal cells rather than PCa-derived epithelial 
cells.  We therefore employed WPMY-1 cells, a prostate myofibroblastic cell line that 
was derived from a human prostate primary stromal culture that was immortalized using 
the SV40 large-T-antigen (114).  Hic-5/ARA55 expression in WPMY-1 cells was 
confirmed by Western blot analysis (Figure 13A).  Immunofluorescence analysis 
revealed that most Hic-5/ARA55 is localized within the cytoplasm and at focal adhesions 
(Figure 13B, top panels).  Although the extent of Hic-5/ARA55 expression within the 
nucleus of WPMY-1 cells was not apparent from the immunofluorescence images, 
Leptomycin B (LMB) treatment of the cells resulted in robust nuclear accumulation of 
Hic-5/ARA55 (Figure 13B, bottom panels).  LMB is an inhibitor of a major nuclear 
export receptor and has been used to reveal the nucleocytoplasmic shuttling properties of 
a variety of proteins, including Hic-5/ARA55 as well as the Hic-5/ARA55 family 
member, zyxin (64, 123).  The effects of LMB on Hic-5/ARA55 localization in WPMY-1 
cells establish that Hic-5/ARA55 is indeed capable of shuttling between the cytoplasmic 
and nuclear compartments and must, therefore, have some residence time within the 




Figure 13.  Expression and nucleocytoplasmic shuttling of Hic-5/ARA55 in the 
WMPY1 prostate stromal cell line.  A, Hic-5/ARA55 expression was analyzed in two 
prostate epithelial cell lines, LNCaP and PC3, as well as a prostate stromal cell line, 
WPMY-1, by Western blot analysis.  Equivalence in protein loading was confirmed by 
reprobing stripped blots with an anti-GAPDH antibody.  B, Immunostaining of 
WMPY1 cells treated with vehicle alone (i and ii) or 100 nM Leptomysin B (LMB) 
(iii and iv) for 3 h and stained with an α-Hic-5/ARA55-specific antibody (i and iii) or 
DAPI (ii and iv).  
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upon LMB treatment (data not shown), indicating that shuttling of Hic-5/ARA55 most 
likely occurs between the cytoplasmic and nuclear compartments.   
 
AR and Hic-5/ARA55 recruitment to the KGF promoter.   
Because Hic-5/ARA55 enhances AR-mediated gene expression in transient transfection 
assays, we set out to reveal whether Hic-5/ARA55 was localized to endogenous 
androgen-responsive promoters in WPMY-1 cells.  KGF is a well established marker of 
androgen induction in prostate stromal cells (19, 20).  As shown in Figures 14A and 14B, 
KGF mRNA expression is induced 2-fold in response to treatment with various 
androgens.  In primary stromal cell cultures, KGF expression is similarly induced 
approximately 2-fold by androgen treatment (20).  Furthermore, androgen induction of 
KGF mRNA expression is blocked by the AR antagonist, hydroxyflutamide, indicating 
that androgen induction of KGF mRNA in WPMY-1 cells is indeed mediated by AR.    
 
Because Hic-5/ARA55 has been found to directly interact with AR, we sought to 
determine if Hic-5/ARA55 is bound to the KGF promoter using ChIP assays and whether 
this binding is affected by androgen treatment.   Detailed analysis of the human KGF 
promoter revealed that promoter proximal sequences located between -225 to +190 were 
necessary for basal KGF expression (124).  Although a canonical hormone response 
element is not located within this region, there is a half-palindromic glucocorticoid 
response element located between positions -178 to -183 around which we designed our 
primers for ChIP analysis (124).  After stimulation with androgens for 1 hour, both AR 





Figure 14.  Androgen-induced KGF expression in WPMY-1 cells.  A,  Androgen effects 
on KGF mRNA expression in WPMY-1 cells was analyzed by RT-PCR.  Gel shown of 
PCR products, resulting from 32 rounds of PCR amplification, following 8 h treatment 
with indicated agents is representative of three separate experiments.  B, Relative changes 
KGF expression were calculated based on semi-quantitative results from scanned images 
as in A.  Values represent KGF expression after normalization with GAPDH ± SD for 
three separate experiments. *, P ‹ 0.05, significantly different from the mean value of 















Figure 15.  Association of AR and Hic-5/ARA55 with the chromatin of the KGF promoter in 
vivo.  ChIP analysis of AR and Hic-5/ARA55 recruitment to the KGF promoter in WPMY-1 cells 
in response to 1 h Mib treatment.  PCR products generated following precipitation of isolated 
chromatin fragments with non-immune IgG, AR or Hic-5/ARA55 antibodies are shown.  PCR 
products in the Input panel were amplified using diluted chromatin that was not 
immunoprecipitated.  Gel shown of PCR products, resulting from 32 rounds of PCR 




 degree of background obtained in ChIP assays with non-immune IgG, it is difficult to 
assess the extent of AR and/or Hic-5/ARA55 binding to the KGF promoter in the absence 
of androgen treatment.  Nonetheless, the ChIP results from hormone treated cells suggest 
that Hic-5/ARA55-mediated coactivation of AR activity in WPMY-1 cells may be 
mediated in part by their recruitment to endogenous androgen-responsive promoters. 
 
Ablation of Hic-5/ARA55 expression results in decreased AR transactivation.   
Given the localization of Hic-5/ARA55 to the KGF promoter in response to androgen 
treatment, we ascertained whether Hic-5/ARA55 was necessary for androgen induction 
of KGF expression using a siRNA approach to ablate Hic-5/ARA55 expression in 
WPMY-1 cells.  WPMY-1 cells were analyzed for Hic-5/ARA55 expression by Western 
blot analysis following transfection with either a control GFP siRNA or Hic-5/ARA55 
siRNA.  Densitometric analysis revealed that there was approximately 60% less Hic-
5/ARA55 in cells transfected with the Hic-5/ARA55 siRNA oligo D as compared to 
control (Figure 16A).  Although this was the maximal amount of Hic-5/ARA55 ablation 
that could be attained with Hic-5/ARA55 siRNA transfections, it was sufficient to reduce 
androgen induction of the transfected androgen-inducible mouse mammary tumor virus 
(MMTV) promoter (Figure 16B) and of endogenous KGF mRNA expression (Figure 
16C).  Basal levels of KGF expression were reproducibly higher upon Hic-5/ARA55 
ablation, suggesting that Hic-5/ARA55 may negatively regulate basal KGF promoter 
activity.  Irrespective of these effects of Hic-5/ARA55 on basal KGF promoter activity, 
 61
the siRNA ablation experiments establish a role for Hic-5/ARA55 in androgen regulation 


















Figure 16.  Effects of RNAi-mediated silencing of Hic-5/ARA55 on AR transactivation.  
A, WPMY-1 cells were transfected with 2 μg GFP (Ct, negative control) or 2 μg human 
Hic-5/ARA55 RNAi constructs (A-D).  After 72 h, cells were harvested, lysed, and 
analyzed for Hic-5/ARA55 and GAPDH protein levels by Western blotting. B, WPMY-1 
 62
cells were transfected with RNAi constructs (GFP and D) as in A as well as the MMTV 
promoter-linked reporter.  After 48 h, the cells were treated with EtOH-vehicle or DHT  
(10-8 M) for 24 h after which luciferase activity was measured.  Data shown are mean of 
three separate experiments.  *, P ‹ 0.05, significantly different from the mean value of 
siGFP controls; bars, SD.  C, Androgen-induced KGF expression was analyzed after 
silencing Hic-5/ARA55.  Cells were transfected as in A.  After 72 h, the cells were 
stimulated with Mib (10-8 M) for 8 h and KGF expression was analyzed by RT-PCR and 
normalized to GAPDH expression.  D, Relative changes KGF expression were calculated 
based on semi-quantitative results from scanned images as in C.  Values represent KGF 






Our results identify Hic-5/ARA55 as a compartment-specific AR coactivator that has an 
impact on androgen regulation of a paracrine growth factor, KGF, in the stroma. The 
importance of KGF in prostate gland development has been revealed by various 
approaches. For example, KGF neutralizing antibodies inhibit prostate epithelial growth 
as well as ductal branching (1).  Furthermore, exogenous KGF was sufficient to produce 




Analysis of Hic-5/ARA55 expression had revealed its limited tissue distribution.  For 
example, immunohistochemical analysis was used to reveal selective expression of Hic-
5/ARA55 in smooth muscle and myoepithelial cells (125). Hic-5/ARA55 was not 
detected in epithelial cells of the tissues examined, including the stomach, colon, liver, 
skin, and mammary gland (125).  Additionally, Hic-5/ARA55 is expressed in the stromal, 
but not epithelial compartment of the prostate (111).  Here, we confirmed the stromal-
specific expression of Hic-5/ARA55 in normal prostate.  Furthermore, Hic-5/ARA55 
expression was also restricted to the stromal compartment in prostate tumor tissue.   
 
The stromal-specific expression of Hic-5/ARA55 suggests that this AR coactivator is 
unlikely to contribute directly to the development or progression of PCa.  However, Hic-
5/ARA55 may play a role in stromal/epithelial cell communication in the prostate since 
androgen induction of a stromal-selective paracine factor (i.e. KGF) is lost upon partial 
ablation of Hic-5/ARA55. Furthermore, the increase in basal KGF expression upon Hic-
5/ARA55 ablation suggests that this coactivator may interact with other transcription 
factors or corepressors to negatively regulate KGF expression in the absence of 
androgens (65). Thus, by serving opposing roles to positively or negatively regulate KGF 
gene transcription, Hic-5/ARA55 may be critical in sculpting tissue organization in the 
prostate, responding to various hormonal and paracrine cues that serve to maintain the 
appropriate balance between distinct stromal and epithelial cell layers. Furthermore, 
given the role of stromal-derived KGF on the growth, transformation, and invasive 
properties of PCa cells, coactivators such as Hic-5/ARA55 may influence tumor 
development and progression through its impact on either basal and/or androgen-induced 
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expression of KGF in stroma during both androgen-dependent and androgen-independent 
phases (126, 127).  
 
Detailed sequence analysis of the human KGF promoter revealed a half-palindromic 
steroid hormone response element between positions -178 to -183, implicating AR 
regulation of KGF transcription (124).  ChIP analysis of the KGF promoter revealed both 
AR and Hic-5/ARA55 recruitment to this region of the KGF promoter in response to 
androgens.  Although most Hic-5/ARA55 is found at focal adhesions and the cytoplasm 
in WPMY-1 cells, Hic-5/ARA55 shuttles between the cytoplasm and the nucleus.  
Interestingly, Hic-5/ARA55 was localized to the KGF promoter in the absence of LMB.  
This indicates that there may be a small pool of Hic-5/ARA55 resident in the nucleus that 
may not be apparent by immunofluorescence analysis, but which nonetheless participates 
in transcriptional regulation of androgen-regulated promoters. 
 
In endocrine target tissues, nuclear receptor activity appears critical for tumor 
development and/or progression (128).  For example, elevated AR expression may be 
necessary for PCa progression to an androgen-independent state (100).  Furthermore, 
increased AR expression correlates with a higher probability of recurrence (101).  In 
response to elevated expression of AR, mutations in AR, or altered expression of 
coactivators, the activity of nuclear receptors within individual cells may exhibit a 
heightened response to non-steroidal signals.  Our work suggests the existence of another 
mechanism for coactivator effects on prostate cancer that does not function in a cell 
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autonomous context.  AR action in cells that support the tumor, located in the stromal 























Chapter 5  Determining the effects of extracellular matrix (ECM) signaling on GR-
mediated transcription in A1-2 cells. 
 
Hypothesis:  Because Hic-5/ARA55 associates with focal adhesion proteins as well as 
nuclear receptors, Hic-5/ARA55 may relay extracellular matrix signals to nuclear 





Intracellular signaling originating from the extracellular matrix (ECM) is mediated by a 
well-established group of receptors known as integrins.  Integrins form heterodimer 
receptors between members of the α and β families, which are specific for an ECM 
component.  For example, α5β6 binds fibronectin primarily, whereas α1β1 binds both 
laminin and collagen (reviewed in (129).  Resulting signals following integrin-ligand 
interactions include modulation of cellular migration, proliferation, survival, and 
apoptosis.  However, the exact mechanism by which ECM signaling influences nuclear 
receptor-mediated gene expression in normal as well as tumorigenic tissue is less clear.   
 
Cross-talk between estrogen receptor (ER) and ECM signaling, resulting in differential 
cell growth and/or gene expression, has been well studied.  Specifically, malignant 
mammary cells grown on a collagen IV or laminin-1 basement membrane express higher 
levels of ERα, resulting in increased ER-mediated gene expression irrespective of the 
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presence of estradiol (130).  Furthermore, analysis of the ERα promoter revealed STAT5 
binding sites located within the region that was responsive to laminin-rich basement 
membranes, indicating that upregulation of ERα expression may be mediated by STAT5 
(131).  However, Woodward et al. report that laminin inhibits ERα activity, namely 
negatively influencing estrogen-mediated progesterone receptor (PR) expression and 
proliferation of breast cancer cells (132).  These discrepancies are most likely due to 
minor differences in the application of the ECM, culturing conditions, and/or the 
differential responsiveness to ECM between different cell lines.   
 
Along with breast cancer cell lines, primary breast epithelial cells also respond to ECM 
signaling.  Epithelial cells derived from nulliparous mice also exhibit increased 
responsiveness to progesterone stimulation when plated on fibronectin or collagen IV 
(133).  After plating the cells on various ECM, increased proliferation in response to 
progesterone treatment was detected in nulliparous-derived but not pregnancy-derived 
breast epithelial cells (133).  These results indicate that mammary gland responsiveness 
to both steroid hormones as well as ECM signaling is dependent on mammary gland 
differentiation. 
 
Although the effects of certain ECM components such as collagen IV and laminin-1 on 
ERα-mediated gene expression have been reported, the exact mechanism by which ECM 
enhances ERα expression and/or activity is unclear.  For example, activation of integrin 
signaling pathways in response to various ECM components may influence nuclear 
receptor phosphorylation, effecting its subcellular localization, coactivator interaction, or 
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protein stability.  Alternatively, ECM may influence nuclear receptor-mediated gene 
expression in a more direct manner, via interaction of focal adhesion-associated proteins 
such as Hic-5/ARA55 with the nuclear receptors, affecting their gene activation. 
 
Along with a possible role for Hic-5/ARA55 in transmitting ECM signals, which in turn 
affect nuclear receptor-mediated gene expression, Hic-5/ARA55 also modulates ECM 
expression.  Using cells that overexpress Hic-5/ARA55, Shibanuma et al. report that Hic-
5/ARA55 expression may influence ECM expression directly (121).  Both collagen and 
fibronectin expression correlated with Hic-5/ARA55 expression (121).  Furthermore, 
overexpression of Hic-5/ARA55 led to alternative splicing of fibronectin, which is also 
associated with the senescence process (121).  The modulation of ECM expression by 
Hic-5/ARA55 may provide a feedback loop, serving to ameliorate or alter ECM signaling 
events.  
 
Here, we examined GR-mediated gene expression in response to various ECM as well as 
Hic-5/ARA55’s role in transmitting ECM-derived signals.  Both fibronectin and matrigel 
influenced GR transactivation in opposing ways.  Matrigel repressed GR-mediated gene 
expression by reducing the levels of GR protein.  Fibronectin did not influence either GR 
or Hic-5/ARA55 expression, subcellular localization or promoter recruitment in the 
presence of ligand, suggesting that other mechanisms by which fibronectin may influence 






Effects of ECM on GR-mediated transcription 
To determine the effects of ECM signaling on GR-mediated gene expression, we took 
advantage of the integrated MMTV promoter in the A-12 cells.  Because T47D cells, the 
parental cell line of A-12 cells, express α1, α3, α4 and α5 integrin subunits, the 
extracellular matrices that were analyzed include:  laminin, collagen, fibronectin as well 
as a growth factor reduced matrigel (136).  Because growth factors such as EGF and IGF-
1 have been reported to activate nuclear receptors-mediated gene expression in the 
absence of ligand, we used a growth factor reduced matrigel to analyze the effects of 
basement membrane components on GR activity (104).  After coating cell culture plates 
with the appropriate ECM, A-12 cells were treated with dex (100 nM) for 18 hours after 
which luciferase reporter activity was measured.  Whereas fibronectin enhanced GR-
mediated luciferase expression in A1-2 cells, matrigel reduced it (Figure 17).  However, 
neither laminin nor vitronectin affected GR transactivation properties.  Furthermore, there 
was no change in GR-mediated gene expression when cells were plated on a nonspecific 
poly-L-lysine substratum, indicating that the responses of GR activity on both fibronectin 
and matrigel were specific and may be mediated by integrin signaling.      
 
Because the effect of fibronectin on GR-mediated gene expression was modest at 100nM 
Dex, we analyzed the effect of fibronectin at lower concentrations of ligand.  Again, 




























































Figure 17.  Effects of extracellular matrices on GR-mediated transcription.  Cell culture plates were 
coated with fibronectin (0.5, 1, and 2.5 μg/cm2), laminin (0.625 and 1.3 μg/cm2), growth factor 
reduced matrigel (undiluted, MG, to diluted 1:1, 1:2 and 1;3), or vitronectin (50, 100, 250 ng/ cm2).  
A1-2 cells were cultured on plastic or fibronectin, laminin, growth factor reduced matrigel, or 
vitronectin.  After 24 hours, the cells were stimulated with either ethanol-vehicle or 100 nM Dex 
for 18 hours after which luciferase activity was measured.  Relative luciferase activities (RLU) 
were normalized to protein concentration by Bradford analysis.  *, P ‹ 0.05, significantly different 







































Figure 18.  Effects of fibronectin on various concentrations of Dex.   A1-2 cells were 
cultured on plastic or fibronectin-coated (1 μg/cm2) plates.  After 24 hours, the cells 
were stimulated with either ethanol-vehicle or 1-100 nM Dex for 18 hours after which 
luciferase activity was measured.  Relative luciferase activities (RLU) were 
normalized to protein concentration by Bradford analysis.  Data shown are the mean 
of three separate experiments.  *, P ‹ 0.05, significantly different from the mean value 





(Figure 18).  Furthermore, at 1nM Dex, fibronectin induced a 2-fold increase in GR 
activity.   
 
Effects of ECM on GR expression 
Because both matrigel and fibronectin influence GR-mediated gene expression in A1-2 
cells, we wanted to determine if this was due to altered GR expression and/or protein 
stability.  After A1-2 cells were plated on the indicated ECM as in Figure 17, cell lysates 
were analyzed for GR expression.  As shown in Figure 19, GR expression was not 
affected when A1-2 cells were plated on fibronectin.  However, plating A1-2 cells on 
matrigel reduced GR levels, thereby, which could account for the repressive effects of 
matrigel on GR-mediated gene expression.  Because Hic-5/ARA55 is localized at focal 
adhesion complexes and also known to influence nuclear receptor-mediated gene 
expression, we also analyzed its expression in A1-2 cells plated on fibronectin or 
matrigel.  Hic-5/ARA55 expression was also reduced by matrigel (data not shown).  
Similar down-regulation of focal adhesion complex proteins including paxillin by 
reduction in protein synthesis along with protease activation has been reported (137).  
This down-regulation was due to inhibition of focal adhesion complex formation when 







Figure 19.  Effects of Matrigel and Fibronectin on GR and Hic-5/ARA55 expression.  Cells 
were cultured on plastic, matrigel, fibronectin as in Figure 16.  A1-2 cell lysates were 
analyzed for GR and Hic-5/ARA55 expression by Western blot analysis using specific 
antibodies.  The membranes were stripped and reprobed with GAPDH-specific antibodies as 









Figure 20.  Effects of fibronectin on nucleocytoplasmic shuttling of GR.  Cells were 
cultured on plastic or fibronectin in Figure 16.  After treatment with vehicle (-) Dex (+, 
100nM) for 1 h, A1-2 cells were harvested and fractionated in order to separate the 
nuclear and cytoplasmic compartments.  Lysates were analyzed for GR expression by 
Western blot analysis using an anti-GR-specific antibody.  Purity of each fractionation 





Effects of fibronectin on nucleocytoplasmic shuttling of GR 
Because fibronectin enhances GR-mediated gene expression, but neither GR nor Hic-
5/ARA55 protein levels, we analyzed GR and Hic-5/ARA55 shuttling in the presence and 
absence of glucocorticoid stimulation.  Ogawa, M et al. report enhanced nuclear  
localization of paxillin in cells plated in vinculin (138).  This altered subcellular 
localization of paxillin in the presence of an extracellular matrix component was 
dependent on MAP Kinase (MAPK) activity, leading to differential phosphorylation of 
paxillin.  In the absence of hormone, most GR is located in the cytoplasm in cells grown 
on plastic or fibronectin (Figure 20).  Upon stimulation with glucocorticoids, GR transits 
to the nucleus with similar efficiency regardless of whether the cells were grown on 
plastic or fibronectin.  Furthermore, there is no change in Hic-5/ARA55 localization upon 
glucocorticoid stimulation in cells plated on either plastic or fibronectin (data not shown).     
 
Effects of cell signaling inhibitors on fibronectin-enhanced GR activity      
To determine the mechanism by which fibronectin stimulates GR-mediated transcription 
in A1-2 cells, we analyzed potential signaling pathways that may act through integrin 
receptors, affecting GR activity.  Both ERK as well as PKB signaling occurs at focal 
adhesions in response to stimulation by extracellular matrices via integrin receptors 
(139).  Using pharmacological inhibitors, U0126 and LY294002, to inhibit ERK and 
PKB signaling respectively, we analyzed GR-mediated gene expression in cells plated on 
both plastic and fibronectin (Figure 21).  Neither U0126 not LY294002 abrogated the 
effect of fibronectin on GR activity.  To ensure that both compounds were active, we 






Figure 21.  Effects of cell signaling inhibitors on fibronectin-enhanced GR activity.  Cells 
were cultured on plastic or fibronectin as in Figure 16.  After 24 hours, the cells were 
stimulated with ethanol-vehicle or Dex (100nM) in the presence or absence of A, ERK 
inhibitor, U0126 (10 μM), or B, PKB inhibitor, LY294002 (10 μM).  Cellular lysates were 
analyzed for phosphorylated ERK or AKT (pERK and pAKT, right panels) by western 
blot analysis in the presence of absence of specified inhibitors.  Total ERK (ERKT) or 






Figure 22.  Effects of fibronectin on GR and Hic-5/ARA55 promoter recruitment in 
response to glucocorticoids.  The cells were plated on plastic (left lanes) or fibronectin 
(right lanes) as before and soluble chromatin was prepared from A1-2 cells treated with 
EtOH-vehicle or Dex (100 nM) for 1 h.  Protein-bound DNA complexes were 
immunoprecipitated with antibodies against GR or Hic-5/ARA55.  After crosslink 
reversal, purified DNA was amplified with primers specific for the MMTV promoter.  
PCR products, resulting from 28 rounds of PCR amplification, in the Input panel were 
amplified using diluted chromatin that was not immunoprecipitated.  A rabbit IgG was 
used to detect any nonspecific immunoprecipitated DNA. 
 
 78
LY294002 respectively.  Both compounds efficiently inhibited phosphorylation of the 
appropriate signaling molecule, indicating that neither ERK nor PKB signaling is 
involved in the effect of fibronectin on GR transactivation. 
 
Effects of fibronectin on GR and Hic-5/ARA55 promoter recruitment in response to 
glucocorticoids 
Because both GR and Hic-5/ARA55 are recruited to glucocorticoid-responsive promoters 
in the presence of hormones, we analyzed the effect of fibronectin on GR and Hic-
5/ARA55 promoter recruitment.  ChIP analysis of the MMTV promoter in A1-2 cells 
plated on plastic or fibronectin revealed that both GR and Hic-5/ARA55 are recruited to 
the promoter upon glucocorticoid stimulation (Figure 22).  Although there was no 
detectable difference in either GR or Hic-5/ARA55 MMTV promoter recruitment in the 
presence of Dex, there may be a slight increase in Hic-5/ARA55 promoter binding in the 
absence of hormone in cells plated on fibronectin.  However, this result is preliminary 






Recent work by various labs has highlighted the responsiveness of nuclear receptors to 
ECM components.  Specifically, Novaro et al. reported that basement membrane 
components such as collagen IV or laminin-1 upregulated ER-mediated gene expression 
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by increasing ERα expression (130, 131).  Furthermore, Sisci et al. described increased 
ERα nuclear localization and ligand-independent activation of gene expression in cells 
plated on either fibronectin or collagen IV (140).  In fact, increased ERα activity in both 
MCF-7 and MDA-MB-231 breast cancer cells was mediated by increased c-Src 
activation after cellular attachment to ECM, thereby affecting cellular mobility  (140).  
Interestingly, increased expression and activity of c-Src has been reported in various 
tumors, including breast cancer, possibly increasing their malignant capabilities (141, 
142). 
 
Using A1-2 breast cancer cells, we analyzed various ECM for their ability to modulate 
GR-mediated transactivation.   Furthermore, because Hic-5/ARA55 is a focal adhesion 
complex-associated protein that influences gene expression, it was postulated that it may 
transmit signaling events from the ECM to the nucleus.  As mentioned previously, it has 
been reported that nuclear accumulation of Hic-5/ARA55 occurs in response to oxidants 
such as H2O2 (64).  Furthermore, using LMB for 1 h in WPMY-1 cells, we were able to 
detect most Hic-5/ARA55 in the nucleus, indicating that Hic-5/ARA55 rapidly transits 
between cytoplasmic and nuclear compartments (Figure 8).   
 
After analyzing various ECM, we determined that both fibronectin and growth factor 
reduced matrigel influenced GR transactivation in A1-2 cells by different mechanisms.  
Matrigel negatively influenced GR-mediated gene expression by reducing GR as well as 
Hic-5/ARA55 expression levels.  Although the exact by which matrigel reduces GR and 
Hic-5/ARA55 expression levels is not known, Wang et al. report a similar reduction of 
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focal adhesion complex proteins such as focal adhesion kinase (FAK) and paxillin by 
matrigel (137).  Both a reduction in protein synthesis as well as activation of calpain 
proteinases resulted in decreased focal adhesion protein levels and was mediated by α2β1 
integrin activity (137).  Following collagen binding, α2β1 integrin signaling may be 
involved in focal adhesion complex formation or stabilization by inducing cytoskeletal 
rearrangements, ultimately affecting cell migration. 
 
Along with matrigel, fibronectin altered GR-mediated gene expression in A1-2 cells, 
increasing GR transactivation.  However, fibronectin failed to modulate GR expression, 
subcellular trafficking, or promoter recruitment.  Hic-5/ARA55 expression and activity 
were also unaffected by fibronectin.  Furthermore, inhibitors of both ERK and PKB 
signaling pathways failed to repress fibronectin-induced GR activation in A1-2 cells.  
However, it is possible that integrin signaling through other proteins may be involved, 
possibly through c-Src.  Furthermore, because the effect of fibronectin on GR-mediated 
gene expression was modest, induction of slight changes in GR expression, subcellular 
trafficking or promoter recruitment may be undetectable.  Alternatively, because ECM 
stimulates numerous intracellular signaling events, fibronectin may promote alternative 
GR phosphorylation, resulting in enhance GR-mediated gene expression.  GR is a 
phosphoprotein, capable of being phosphorylated at multiple sites, some of which induce 
greater GR nuclear localization and activity (143).  A detailed analysis of the 
phosphorylation state of GR in cells plated on fibronectin will determine if that is the 
mechanism by which fibronectin enhances GR-mediated gene expression.   
 
 81
CHAPTER 6  DISCUSSION 
 
The aim of this project was to determine the mechanism by which Hic-5/ARA55 serves 
as a nuclear receptor coactivator as well as determining its potential involvement in PCa 
progression.  Tumorigenesis is a multi-step process which involves changes in not only 
the malignant cells but also the surrounding microenvironment of that tumor, including 
stromal cells and ECM.  Because Hic-5/ARA55 is a nuclear receptor coactivator that is 
involved in cellular differentiation as well as growth, analysis of its expression and 
activity may illuminate certain aspects of prostate cancer initiation or progression.   Our 
results identify Hic-5/ARA55 as a compartment-specific AR coactivator that has an 
impact on androgen regulation of a paracrine growth factor, KGF, in the stroma.  
 
Hic-5/ARA55-coregulator interactions  
 
In recent years, numerous nuclear receptor-interacting proteins have been identified that 
modify chromatin, thereby influencing nuclear receptor-mediated gene expression.  
Because assays using reporter gene analysis to determine nuclear receptor activity 
revealed that overexpression of most coactivators enhanced the activity of many nuclear 
receptors, coactivator specificity was questioned.  Hence, it was postulated that 
coactivators function in a cell type or promoter-specific manner.  Using the MMTV 
promoter, Li et al. isolated a specific coactivator complex that associated with PR that 
differed to the coactivator complex which bound to GR (14).  These results indicate that 
combinations of coactivators rather than individual coactivators may be responsible for 
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promoter or hormone-specific gene expression.  Furthermore, coactivator knock out 
analysis provided evidence that at least in part, coactivator function is not totally 
redundant.   For example, TIF-2 and RAC3 null mice display reduced reproductive 
capability while SRC-1 null mice are exhibit partial hormone resistance (41, 42).   
 
Along with coactivators that modify chromatin, other coactivators such as Hic-5/ARA55 
have been discovered whose mechanism of action is largely unknown.  Because Hic-
5/ARA55 does not possess a catalytic domain that is responsible for its coactivation 
properties, its mechanism of coregulator function has remained undefined.  However, it 
may serve as an adaptor molecule, either recruiting or stabilizing promoter-specific 
protein complexes.  LIM proteins are well recognized for their roles as molecular 
adaptors, functioning in stabilizing higher order protein complexes at either focal 
adhesion complexes or promoter sequences.  siRNA ablation experiments reported here 
establish that Hic-5/ARA55 is required for the stable association of p300 and TIF-2 with 
the MMTV promoter (Figure 6).  Thus, Hic-5/ARA55 may stabilize select protein 
complex formation at GR-responsive promoters by serving as an adaptor molecule.   
 
Not only does Hic-5/ARA55 interact with various coactivator complexes, but it also 
associates with NCoR corepressor complexes in the absence of hormone at nuclear 
receptor-responsive promoters (Figure 5C).  This suggests that Hic-5/ARA55 is capable 
of interacting with other coregulators directly not necessarily via nuclear receptors.  
Furthermore, because Hic-5/ARA55 is present on GR-responsive promoters in the 
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absence and presence of glucocorticoids, it may function in coordinating corepressor 
release and coactivator recruitment upon glucocorticoid stimulation. 
 
Recently, transducin β-like 1 (TBL1), an adaptor-like protein, has been reported to 
mediate the exchange of corepressors for coactivators on nuclear receptor-responsive 
promoters in response to ligand (144).  TBL1 was initially isolated as part of the 
corepressor complex (145).  ChIP analysis of nuclear receptor target promoters revealed 
prolonged TBL1 promoter association in the presence of ligand (144).  Furthermore, 
TBL1 recruited proteosome machinery to nuclear receptor target promoters, leading to 
degradation of the corepressor complex followed by association of the coactivator 
complex (144).  Although the possible interaction of Hic-5/ARA55 with components of 
the proteosome machinery has not been analyzed, it may provide a mechanism by which 
Hic-5/ARA55 interacts with both corepressors and coactivators, culminating in enhanced 
nuclear receptor-mediated gene expression. 
 
Although Hic-5/ARA55 was localized to GR-responsive promoters in the absence of 
ligand and detectable promoter-bound GR, the mechanism by which Hic-5/ARA55 is 
bound in the absence of receptor is unclear.  In addition to receptor-independent binding 
of Hic-5/ARA55 to the MMTV promoter, we also isolated receptor-independent 
localization of NCoR to the MMTV promoter in the absence of ligand.  Direct binding of 
either Hic-5/ARA55 or NCoR to the MMTV promoter has not been analyzed.  
Interestingly, Hic-5/ARA55 does display zinc-dependent DNA binding (146).  However, 
a specific DNA sequence for which Hic-5/ARA55 is capable of binding has yet to be 
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identified.  Instead, it is thought that Hic-5/ARA55 may be capable of binding DNA in a 
more non-specific manner.  If Hic-5/ARA55 is capable of directly binding the MMTV 
promoter, it may function in tethering the NCoR-containing complex to the MMTV 
promoter in the absence of ligand.  However, it is also possible that both Hic-5/ARA55 
and NCoR are binding the MMTV promoter through another, yet unidentified DNA 
binding protein. 
 
Although Hic-5/ARA55 interactions with other coactivators as well as NCoR were 
observed in the A1-2 cells, we anticipate that similar interactions would be found in the 
WMPY-1 stromal cells.  Specifically, we detected Hic-5/ARA55 bound to the KGF 
promoter in the absence of androgens (Figure 15).  Ligand independent promoter 
localization of Hic-5/ARA55 was also observed in the A1-2 cells.  Furthermore, addition 
of ligand enhanced the amount of Hic-5/ARA55 promoter recruitment in both cell lines.  
Because Hic-5/ARA55 is found within coactivator as well as corepressor complexes in 
A1-2 cells, we anticipate that similar interactions may occur in WPMY-1 cells, possibly 
in a promoter-specific manner. 
 
Coactivators and PCa  
 
Because some steroid-responsive nuclear receptors such as AR and ER have been 
associated with cancers derived from endocrine target tissues, their expression as well as 
coactivator expression and activity has been analyzed in breast as well as PCa.  As 
previously mentioned, treatment of PCa with anti-androgen therapy initially thwarts 
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tumor growth.  However, most PCa eventually progresses into a hormone refractory, 
androgen-independent PCa, capable of growth in the presence of anti-androgens.  
Although the exact mechanism by which PCa becomes androgen-independent is unclear, 
coactivator expression and/or activity may be involved.  As previously mentioned, altered 
expression of coactivators may enhance ligand-independent AR activity in androgen 
independent prostate cancer.  For example, increased TIF-2 expression enhanced AR-
mediated gene expression in response to estradiol as well as progesterone (106).  
Interestingly, Hic-5/ARA55 expression was reduced in tumor as compared to normal 
tissue (112).  Furthermore, Hic-5 mRNA levels were lower in hormone-refractory PCa 
than that of previously untreated PCa.  In recurrent hormone refractory PCa, higher Hic-
5/ARA55 expression correlated with unfavorable recurrence-free survival as well as 
overall survival (122).  Because most analyses of coactivator expression in PCa 
progression use quantitative PCR analysis of whole prostate tissue sections, it is difficult 
to ascertain whether this represents reduced expression of Hic-5/ARA55 within 
individual cells or alterations in the balance between stromal/epithelial cell content in 
tumors.  Subsequent analysis of Hic-5/ARA55 expression in primary prostate stromal 
cells derived from normal or tumor prostates revealed reduced Hic-5/ARA55 expression 
in tumor stromal cells (unpublished data).  However, analysis of Hic-5/ARA55 
expression in prostate tissue sections indicated that there was some continued expression 
of Hic-5/ARA55 in prostate tumors (Figure 12). 
 
Because partially silencing Hic-5/ARA55 expression in WMPY-1 cells resulted in 
increased basal KGF expression, we anticipate that reduced Hic-5/ARA55 expression in 
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reactive stromal cells may also result in increased KGF expression.  In fact, KGF 
expression is significantly increased in prostate cancer (22).  Enhanced KGF expression 
possibly due to reduced Hic-5/ARA55 expression may result in androgen-independent 
activation of AR or increased tumor epithelial proliferation, thereby promoting androgen-
independent PCa progression.  
 
Reactive Stromal Transition 
 
Along with changes in the epithelia compartment, which is the source of tumor cells, 
development of an altered stromal microenvironment, termed reactive stroma, carcinoma 
associated fibroblasts (CAF) or tumor stroma, enhances tumor cell survival, cellular 
proliferation, and migration (81, 82).  The presence of undifferentiated myofibroblast 
cells which express both smooth muscle cell and fibroblasts markers induces changes in  
ECM expression as well (83).  Myofibroblasts are commonly found at areas undergoing 
tissue remodeling, producing ECM such as collagen I and fibronectin as well as 
proteases, including matrix metalloproteinases (MMPs) (84-86).  Along with altered 
ECM expression by reactive stromal cells, data indicate altered gene expression of 
growth factors such as KGF, FGF-2, TGF-β, and IL-6, and matrix metalloproteinases in 
reactive stromal cells (22, 89-92).  The differential gene expression pattern induced by 
the reactive stroma may confer resistance to cell cycle inhibitors or metastatic properties 
to the malignant cells.  As mentioned previously, TGF-β may be involved in the 
progression to a reactive stroma phenotype by inducing myofibroblast formation (83).  
Interestingly, TGF-β induces Hic-5/ARA55 expression in fibroblasts although it is 
 87
unclear whether its expression is upregulated in reactive stromal cells.  Because Hic-
5/ARA55 is involved in both ECM and KGF expression in normal prostate stromal cells, 
upregulation of Hic-5/ARA55 expression resulting from increased TGF- β stimulation 
could result in differential ECM as well as KGF production.  
 
Hic-5/ARA55 and development 
 
During tissue development, progenitor cells terminally differentiate whereby they usually 
exit the cell cycle as well as phenotypically differentiate.  Hic-5/ARA55 expression has 
been shown to both induce and repress cellular differentiation in a cell type-specific 
manner.  For example, rat calvarial bone cells (RCT-1) differentiate into osteoblasts after 
retinoic acid treatment, which decreases cell growth and induces alkaline phosphatase 
and α I pro-collagen expression (147).  During RCT-1 differentiation, Hic-5/ARA55 
expression is upregulated (147).  Furthermore, overexpression of Hic-5/ARA55 in RCT-1 
cells leads to decreased cellular proliferation as well as increased αI pro-collagen 
synthesis, both indicative of osteoblast differentiation (147).  Alternatively, during 
myogenesis, Hic-5/ARA55 expression correlates with apoptotic myoblasts (148).  The 
process of myogenesis is characterized by myoblast fusion and induction of muscle-
specific gene expression, culminating in myotubule formation.  Myoblasts that fail to 
differentiate undergo apoptosis, and Hic-5/ARA55 expression not only blocks 
myogenesis but also induces apoptosis in mouse C2C12 myoblasts (148). 
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Along with either promoting or inhibiting cellular differentiation, Hic-5/ARA55 may also 
be involved cell type-specific differentiation programs.  For example, Hic-5/ARA55 is 
expressed in gut epithelial cells during development (66).  Furthermore, it serves as a 
coactivator for PPARγ-mediated gene expression in intestinal epithelial cells.  Partial 
ablation of Hic-5/ARA55 expression repressed PPARγ-mediated expression of keratin 
20, L-FABP, and KLF.  Finally, expression of Hic-5/ARA55 in preadipocytes not only 
inhibits adipogenesis but also induces epithelial gene expression in these mesenchymal 
cells, suggesting that Hic-5/ARA55 regulates epithelial gene expression in the gut (66).  
Interestingly, TBL1, another nuclear receptor associated- adaptor protein, expression is 
necessary for PPARγ-induced adipogenesis (144). 
 
We show here a role for Hic-5/ARA55 in KGF expression in WPMY-1 human stromal 
cells of the prostate.  KGF, a crucial mediator of epithelial-stromal interactions during 
prostate development, is regulated by androgens.  For example, KGF neutralizing 
antibodies inhibit prostate epithelial growth as well as ductal branching (1).  Furthermore, 
addition of exogenous KGF to a serum-free organ culture system leads to prostate growth 
as well as ductal branching, overcoming the requirement for testosterone (1).  As shown 
in Figure 10, androgen regulation of KGF expression is mediated by AR recruitment to 
the KGF promoter.  Silencing of Hic-5/ARA55 expression led to increased basal 
expression of KGF in the absence of androgens (Figure 16).  Furthermore, the increase in 
basal KGF expression upon Hic-5/ARA55 ablation suggests that this coactivator may 
interact with other transcription factors or corepressors to repress KGF expression in the 
absence of androgens (65).  By partially silencing Hic-5/ARA55 expression in WPMY-1 
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cells, Hic-5/ARA55-mediated repression may be removed, leading to KGF expression in 
the absence of androgens.  Furthermore, AR recruitment to the KGF promoter along with 
subsequent coactivator interactions in the presence of androgens may negate the 
repression by Hic-5/ARA55, resulting in androgen-induced KGF expression.  In A1-2 
cells, the enhanced association of NCoR with Hic-5/ARA55 complexes at the MMTV 
promoter in non-hormone treated cells suggests that Hic-5/ARA55 may, in fact, 
participate in maintaining low basal levels of transcription from this promoter.  Thus, by 
serving opposing roles to positively or negatively regulate KGF gene transcription, Hic-
5/ARA55 may be critical in sculpting tissue organization in the prostate, responding to 
various hormonal and paracrine cues that serve to maintain the appropriate balance 
between distinct stromal and epithelial cell layers.  Indeed analysis of Hic-5/ARA55 
expression during prostate development may be beneficial in determining the mechanism 
by which Hic-5/ARA55 and AR regulation of KGF expression may be involved in 
prostate development. 
 
Hic-5/ARA55 and cell growth 
 
As mentioned previously, Hic-5/ARA55 negatively affects cell growth in both 
osteoblasts and myoblasts (147, 148).  In nontumorigenic, immortalized human 
fibroblasts, overexpression of Hic-5/ARA55 induced senescence (121).  Cellular 
senescence or cellular aging is characterized by an irreversible growth arrest.  
Interestingly, p21 (Cip1/WAF1/sdi1) cyclin-cdk inhibitor, a gene that is induced during 
senescence, is upregulated in cells that overexpress Hic-5/ARA55 (121, 149).  As shown 
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in Figures 3 and 4, Hic-5/ARA55 is recruited to the p21 promoter after glucocorticoid 
stimulation, and silencing Hic-5/ARA55 reduced glucocorticoid-induced p21 expression.  
It is possible that overexpression of Hic-5/ARA55 during senescence may induce p21 
expression directly, thereby overcoming the need for glucocorticoid induction.  
Furthermore, induction of c-fos expression upon serum stimulation is lost in cells 
undergoing senescence, inhibiting cellular proliferation (150).  In Hic-5/ARA55 
overexpressing cells, c-fos induction upon TPA stimulation is lost as well (121).  
However, H2O2 treatment, inducing Hic-5/ARA nuclear localization, upregulated c-fos 
expression in TIG-7 human fibroblasts (64).  In A1-2 cells, we saw no effect on c-fos 
expression upon Hic-5/ARA55 depletion, suggesting that Hic-5/ARA55 expression is not 
necessary for c-fos induction by glucocorticoids in nonsenescent cells (Figure 4).   
 
The recent demonstration of Hic-5/ARA55 involvement in PPARγ-induced epithelial cell 
differentiation program illustrates the importance of “adaptor” coactivators that lack 
enzymatic activity in assembling functional coregulator complexes on distinct promoters.  
More detailed analysis of this novel family of nuclear receptor coactivators may unlock 
multiple nuclear receptor gene networks that utilize LIM domain-containing adaptors to 
organize gene-specific coactivator assemblies.  In conclusion, given the role of stromal-
derived KGF on the growth, transformation, and invasive properties of PCa cells, 
coactivators such as Hic-5/ARA55 may influence tumor development and progression 
through its impact on either basal and/or androgen-induced expression of KGF in stroma 
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